ACC/AHA/SCAI Health Policy Statement

ACC/AHA/SCAI 2014 Health Policy Statement on Structured Reporting for the Cardiac Catheterization Laboratory

A Report of the American College of Cardiology Clinical Quality Committee

Developed in Collaboration With the American Association for Critical-Care Nurses, Asian Pacific Society of Cardiology, Canadian Cardiovascular Society, Health Level Seven International, Inter-American Society of Cardiology, Integrating the Healthcare Enterprise, Society of Thoracic Surgeons, and Society for Vascular Surgery

WRITING COMMITTEE MEMBERS

Timothy A. Sanborn, MD, MS, FACC, FAHA, FSCAI, Chair*; James E. Tcheng, MD, FACC, FSCAI, Vice-Chair*; H. Vernon Anderson, MD, FACC, FSCAI*; Charles E. Chambers, MD, FACC, FSCAI†; Sharon L. Cheatham, PhD, APRN‡; Matthew V. DeCaro, MD, FACC; Jeremy C. Durack, MD§; Allen D. Everett, MD, FACC*; John B. Gordon, MD, FACC*; William E. Hammond, PhD‖; Ziyad M. Hijazi, MBBS, MPH, FACC‡; Vikram S. Kashyap, MD, FACC§; Merrill Knudston, MD, FRCP(C), CM¶; Michael J. Landzberg, MD, FACC**; Marco A. Martinez-Rios, MD, FACC, FIACC, FSCAI††; Lisa A. Riggs, CNSS‡‡; Kui Hian Sim, MBBS, FACC, FSCAI§§; David J. Slotwiner, MD, FACC‖‖; Harry Solomon‖‖‖; Wilson Y. Szeto, MD##; Bonnie H. Weiner, MD, FACC, FSCAI†; William S. Weintraub, MD, FACC, FAHA; John R. Windle, MD, FACC*

*American College of Cardiology Representative. †Society for Cardiovascular Angiography and Interventions Foundation Representative. ‡American Heart Association Representative. §Society of Interventional Radiology. ¶Health Level Seven International. §§Society for Vascular Surgery. ††Canadian Cardiovascular Society. ‡‡International Society for Adult Congenital Heart Disease. ‡§Inter-American Society of Cardiology. ‡‖American Association for Critical-Care Nurses. §§§Asian Pacific Society of Cardiology. ‡‖‖Integrating the Healthcare Enterprise. †††Digital Imaging and Communications in Medicine. §§§Society of Thoracic Surgeons. ‡‡‡Clinical Quality Committee representative during this writing effort.

Author Recusals: Writing committee members are required to recuse themselves from voting on sections to which their specific relationship with industry and other entities may apply; see Appendix I for recusal information.

This document was approved by the American College of Cardiology Board of Trustees, the American Heart Association Science Advisory and Coordinating Committee, and the Society for Cardiovascular Angiography and Interventions Foundation Board of Trustees in February 2014; and endorsed by the American Association for Critical-Care Nurses Board of Directors, the EXCO Committee of the Asian Pacific Society of Cardiology, the Canadian Cardiovascular Society Executives and Council, Health Level Seven’s Board of Directors, Inter-American Society of Cardiology Comité Ejecutivo, Integrating the Healthcare Enterprise International Board, the Society of Thoracic Surgeons Board of Directors, and the Society for Vascular Surgery Board of Directors in March 2014. For the purpose of complete transparency, disclosure information for the ACC Board of Trustees, the board of the convening organization of this document, is available at: http://www.cardiosource.org/ACC/About-ACC/Leadership-Officers-and-Trustees.aspx. ACC board members with relevant relationships with industry to the document may review and comment on the document but may not vote on approval.

The online-only Comprehensive Relationships Data Supplement is available with this article at http://circ.ahajournals.org/lookup/suppl/doi:10.1161/CIR.0000000000000043/-/DC1.

The online-only Data Supplement file is available with this article at http://circ.ahajournals.org/lookup/suppl/doi:10.1161/CIR.0000000000000043/-/DC2.


This article has been copublished in Journal of the American College of Cardiology.

Copies: This document is available on the World Wide Web sites of the American College of Cardiology (www.cardiosource.org), the American Heart Association (my.americanheart.org), Society for Cardiovascular Angiography and Interventions (www.scai.org), Health Level Seven International (www.hl7.org), Integrating the Healthcare Enterprise (www.ihe.net/), Society of Thoracic Surgeons (www.ssts.org/), and Society for Vascular Surgery (www.vascularweb.org/Pages/default.aspx). A copy of the document is available at http://my.americanheart.org/statement by selecting either the “By Topic” link or the “By Publication Date” link. To purchase additional reprints, call 843-216-2533 or e-mail kelle.ramsay@wolterskluwer.com.

Expert peer review of AHA Scientific Statements is conducted by the AHA Office of Science Operations. For more on AHA statements and guidelines development, visit http://my.americanheart.org/statements and select the “Policies and Development” link.

Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the American Heart Association. Instructions for obtaining permission are located at http://www.heart.org/HEARTORG/General/Copyright-Permission-Guidelines_UCM_300404_Article.jsp. A link to the “Copyright Permissions Request Form” appears on the right side of the page.

(Circulation. 2014;129:2578–2609.)

© 2014 by the American College of Cardiology Foundation, the American Heart Association, Inc., and the Society for Cardiovascular Angiography and Interventions Foundation.

Circulation is available at http://circ.ahajournals.org

DOI: 10.1161/CIR.0000000000000043
Table of Contents

1. Introduction .......................................................... 2580
   1.1. Document Development Process .......................... 2580
       1.1.1. Writing Committee Organization .................. 2580
           1.1.2. Document Development and Approval ............. 2581
   1.2. Background and Rationale ................................... 2581
2. Principles of Structured Reporting ............................ 2582
   2.1. General Principles .......................................... 2582
   2.2. Integration of Data Acquisition .......................... 2583
       With Workflow .................................................. 2583
   2.3. Capture of Information as Data ............................. 2584
       Rather Than Prose .............................................. 2584
   2.4. Role of the Physician in Authoring the ......... 2585
       Structured Procedure Report .................................. 2585
   2.5. The Best Practice Model .................................... 2585
3. Catheterization Procedure Reporting: .......................... 2586
   3.1. The Procedure Log Report ................................. 2586
   3.2. The Physician-Authored Structured Procedure Report .... 2587
4. The Prototype Formatted, Tabular, Structured Procedure Report ........................................ 2587
   4.1. Front Page Summary: Highest Value Information ........... 2588
   4.2. Graphics and Images Section ................................ 2588
   4.3. Report Body: Details ......................................... 2588
       4.3.1. Administrative Information ......................... 2589
           4.3.2. History and Risk Factors ......................... 2590
           4.3.3. Procedure Details .................................. 2590
           4.3.4. Diagnostic Results .................................. 2591
           4.3.5. Intervention ......................................... 2591
           4.3.6. Final Diagnoses ...................................... 2591
           4.3.7. Operators, Titles, Regulatory Attestation .......... 2594
   4.4. Procedure-Specific Content ................................ 2594
       4.4.1. Cardiac Catheterization (Right, Left, .... 2594
                   Coronary Intervention) ............................ 2594
       4.4.2. Peripheral Vascular Catheterization ............... 2595
       4.4.3. Cerebrovascular Catheterization .................... 2596
       4.4.4. Valvular Heart Disease: Transcatheter .... 2596
               Aortic Valve Replacement ............................ 2596
       4.4.5. Congenital and Structural Heart ....... 2597
               Catheterization ........................................ 2597
       4.4.6. Combination Procedures ............................... 2597

4.5. Structured Report Style Guide .............................. 2597
4.6. Data Export ..................................................... 2598
4.7. Paradigm Expansion .......................................... 2598
5. Adoption and Implementation ...................................... 2600
6. Extending the Structured Reporting Use Case ........................ 2601
References .................................................................. 2601

Appendix 1. Author Relationships With Industry and Other Entities (Relevant) ........................................ 2603
Appendix 2. Peer Reviewer Relationships With Industry and Other Entities (Relevant) .................. 2605
Appendix 3. Abbreviations ............................................... 2609

Preamble

This document has been developed as a health policy statement (HPS) by the American College of Cardiology (ACC). HPSs are intended to promote or advocate a position, be informational in nature, and offer guidance to the stakeholder community regarding the stance of the ACC and other contributing organizations on healthcare policies and programs. HPSs are not intended to offer clinical guidance and do not contradict existing ACC clinical policy. They are overseen by the ACC Clinical Quality Committee (CQC), the group responsible for developing and implementing all HPS policies and procedures related to topic selection, commissioning writing committees, and defining document development methodologies. The CQC brings together various areas of the College such as the Advocacy Committee, the National Cardiovascular Data Registry (NCDR), the ACC/American Heart Association (AHA) Task Forces on Guidelines and Performance Measurement, and the ACC Appropriate Use Criteria (AUC) Task Force.

The CQC recommended the development of this HPS to document the ACC’s official position on structured reporting of cardiac catheterization procedures. A number of organizations were invited to coauthor this statement with the goal of sharing a unified message on this important topic. Structured reporting is believed to be foundational to the provision of high-quality care for patients undergoing procedures in the cardiac catheterization laboratory. As such, the intended audience for this document includes third-party payers; electronic health record (EHR) and clinical software vendors; accrediting and certifying organizations; and regulators whose areas of responsibility include electronic health data.

To avoid actual, potential, or perceived conflicts of interest that may arise as a result of industry relationships or personal interests among the writing committee, all members of the writing
committee, as well as peer reviewers of the document, are asked to disclose all current healthcare-related relationships, including those existing 12 months before initiation of the writing effort. The CQC reviews these disclosures to determine what companies make products (on market or in development) that pertain to the document under development. On the basis of this information, a writing committee is formed to include a majority of members with no relevant relationships with industry and other entities (RWI), led by a chair with no relevant RWI. Authors with relevant RWI are not permitted to draft initial text or vote on recommendations pertaining to their RWI. RWI is reviewed on all conference calls and updated as changes occur. Author and peer reviewer RWI pertinent to this document are disclosed in Appendices 1 and 2, respectively. In addition, to ensure complete transparency, authors’ comprehensive disclosure information—including RWI not pertinent to this document—is available as an online supplement. Disclosure information for the ACC CQC is also available online at http://www.cardiosource.org/ACC/About-ACC/Who-We-Are/Leadership/Guidelines-and-Documents-Task-Forces.aspx, as well as the ACC disclosure policy for document development at http://www.cardiosource.org/Science-And-Quality/Practice-Guidelines-and-Quality-Standards/Relationships-With-Industry-Policy.aspx. The work of the writing committee was supported exclusively by the ACC without commercial support. The writing committee members volunteered their time to this effort. Conference calls of the writing committee were confidential and attended only by committee members.

Joseph P. Drozda, Jr., MD, FACC
Chair, ACC Clinical Quality Committee

Executive Summary

The final report is an essential component of every invasive and operative procedure. This vital document records key data used to assess indications and appropriateness of care, details technical aspects of the procedure, describes findings and observations, lists results and calculations, provides the interpretation of the study, and conveys patient care recommendations. In addition to providing essential information to the entire team of care providers, the final report is utilized in billing and inventory management, process and performance improvement, outcomes analysis, teaching and education, and as a data source for registries.1 The final report is a legal medical record document and should be of the highest quality so as to optimize both patient outcomes and institutional operational efficiencies. A structured report generated by a structured reporting process is the most suitable vehicle for these goals, but this approach is only slowly being adopted despite prior recommendations and endorsements. This HPS is intended to provide a general model for structured reporting for invasive and interventional cardiovascular procedures and thus catalyze and accelerate implementation of structured reporting. Through endorsement of this document, the cardiovascular community recognizes the critical importance of structured reporting and calls for its uniform adoption.

The general principles of structured reporting in cardiovascular imaging are well established. Information should be captured as data rather than prose; these data should flow bidirectionally to and from the EHR for subsequent presentation and analysis. The final report should be clear, concise, organized, consistent, reproducible, understandable, and in a format that is flexible to accommodate evolutionary procedural changes and documentation requirements.

Key considerations for generating a structured report are discussed in detail, with a structured procedure report prototype included for modeling purposes. The prototype final report is segmented into 3 principal sections. The first section (front page) is a single (physical) page that contains the highest value clinical information. Because angiography is inherently visual, the second section is dedicated to the graphical representations of the findings and (optionally) images imported into the report. The body (third section) contains all of the remaining data presented as a series of structured, formatted tables. Procedure-specific content is outlined for diagnostic cardiac catheterization, percutaneous coronary intervention (PCI), peripheral vascular and cerebral vascular procedures, valvular heart disease including transcatheter aortic valve replacement (TAVR), structural and congenital heart disease (CHD), and combination procedures. The concepts enumerated in this HPS are applicable to nonsurgical endovascular procedures performed in a cardiac catheterization laboratory, hybrid catheterization/operating room suite, and interventional/neuroradiology suite.

Universal adoption of structured reporting for invasive cardiovascular imaging procedures requires the acknowledgment of its potential benefits and acceptance of the responsibilities entailed. In order to stimulate structured reporting implementation, key groups including physician operators, catheterization laboratory personnel, the software vendor community, and leadership of registries must be on the forefront of advocating the adoption of structured reporting. The ACC/AHA/Society for Cardiovascular Angiography and Interventions Foundation (SCAI) recognize that the development and deployment of structured reporting will be an ongoing process and, therefore, strongly encourage the view that structured reporting be considered one component of the overall quality improvement imperative for cardiovascular care.

1. Introduction

1.1. Document Development Process

1.1.1. Writing Committee Organization

The writing committee consists of a broad range of members from the ACC as well as the following societies: American Association of Critical-Care Nurses (AACN), AHA, Asian Pacific Society of Cardiology (APSC), Canadian Cardiovascular Society (CCS), Digital Imaging and Communications in Medicine (DICOM), Health Level Seven International (HL7), Inter-American Society of Cardiology (IASC), Integrating the Healthcare Enterprise (IHE), International Society for Adult Congenital Heart Disease (ISACHD), SCAI, Society of Interventional Radiology (SIR), Society of Thoracic Surgeons (STS), and Society for Vascular Surgery (SVS). Representatives from these societies included those with expertise in cardiothoracic surgery, interventional cardiology, interventional radiology, general cardiology, echocardiography, and cardiac nursing. Along with these specialties, specific knowledge in the areas of TAVR, carotid and cerebrovascular disease, vascular medicine, structural heart disease, patient outcomes, data interoperability, and catheterization laboratory workflows were also reflected in the workgroup to provide an
appropriate balance of perspectives. Geographically, the writing committee included both domestic and international members.

Relationships with EHR companies and software vendors active in cardiovascular medicine were deemed relevant to this writing effort. This writing committee met the College’s disclosure requirements for RWI as described in the Preamble.

1.1.2. Document Development and Approval

The writing committee convened by conference call and e-mail to finalize the document outline, develop the initial draft, revise the draft per committee feedback, and ultimately approve the document for external peer review. Each participating organization provided peer reviewers, resulting in 32 reviewers representing 410 comments. To increase its applicability further, the document was posted online for a 3-week public comment period, resulting in 40 additional comments. All comments were reviewed and addressed by the writing committee, resulting in change to the manuscript. A member of the ACC CQC served as lead reviewer to ensure that all comments were addressed adequately. Both the writing committee and CQC approved the version of the final document sent for board review. The ACC Board of Trustees, the AHA Science Advisory and Coordinating Committee, and the Society for Cardiovascular Angiography and Interventions Foundation Board of Trustees reviewed the document, including all peer review comments and writing committee responses, and approved the document in February 2014. The AACN, APSC, CCS, HL7, IASC, IHE, STS, SVS, endorsed the document in March 2014. This document is considered current until the CQC revises or withdraws it from publication.

1.2. Background and Rationale

A final procedure report is essential and required for all cardiovascular catheterization procedures. The procedure report documents key data used to assess indications and appropriateness of care, details technical aspects of the procedure, describes findings and observations, lists results and calculations, provides the interpretation of the study, and conveys patient care recommendations. It is a vital means of communication between the physician operator and the team of care providers. Additionally, it is utilized in billing and inventory management, process and performance improvement, patient outcomes analysis, teaching and education, and participation in data registries. The final procedure report is a legal medical record document often accessible to patients via internet portals and personal health records. Patient education, enablement, and participation in their health care are augmented by unambiguous information returned to the patient, a movement that is facilitated by better procedure reporting. Accordingly, it is imperative that complete reports of the highest quality are authored. Elements of quality achieved through structured reporting include clarity and completeness of documentation, consistency in the organization and presentation of information, and fulfillment of requirements for quality reporting, regulatory compliance, coding and billing, all while reducing the time devoted to documentation and improving operator efficiency. Furthermore, structured reporting creates the potential for patient-specific risk prediction (e.g., bleeding, restenosis, mortality) and other types of clinical decision support at the point of care.

The concept of a structured procedure report is not new. In 2006, a multistakeholder group recommended the use of structured reports as a key component to achieving quality in cardiovascular imaging. The subsequent “2008 ACCF/ACR/AHA/ASE/ASNC/HRS/NASCI/RSNA/SAIP/SCAI/SCCT/SCMR HPS on Structured Reporting in Cardiovascular Imaging” articulated the framework for structured reporting for cardiovascular imaging procedures. Structured reporting was again endorsed in the “2012 ACCF/SCAI Expert Consensus Document on Cardiac Catheterization Laboratory Standards Update” as the instrument for documenting cardiac catheterization laboratory procedures. Nonetheless, adoption of structured reporting has been slow, and even today the majority of catheterization reports are dictated and transcribed in unstructured formats. Even when structured reporting is used, there is a lack of consistency from laboratory to laboratory, and from vendor to vendor. This suggests several reasons for the failure to universally adopt structured reporting: insufficient understanding of the specifics of structured reporting; inadequate guidance to both the clinical community and administrative management as to exactly what to demand; and an absence of sufficient economic, professional, and regulatory motivation to adopt structured reporting as a “requirement.” This HPS addresses these dimensions, leveraging advances in standards (such as the HL7 Consolidated Clinical Document Architecture [C-CDA]) and the Integrating the Healthcare Enterprise Cath Report Content [IHE CRC] profile to provide explicit technical specifications while articulating the clinical, scientific, social, economic, and regulatory advantages of structured reporting in the cardiovascular catheterization suite.

It is critical to differentiate the narrow concept of the “structured report” from the more comprehensive process of “structured reporting.” Structured reporting begins with the explicit use of standardized, controlled vocabularies of clinical data elements, integrates workflow and documentation processes, and achieves data interoperability among information technology systems as a natural and intended result. The authoring of formatted, structured catheterization procedure reports in a coherent, consistent, and clinically relevant manner is perhaps the most valuable outcome of a structured reporting environment. However, this HPS purposefully expands beyond the narrow concept of the structured report to include the entire data acquisition and reporting process.

Controlled vocabularies are selected lists of words and phrases (standardized data elements) with explicit definitions that convey specific (human interpretable) meaning while achieving computational interoperability. Controlled vocabularies are foundational to structured reporting because they enable the computational assessment of systems, processes, performance, and outcomes. The consistent use of controlled vocabularies among disparate encounters allows organizations to assess procedure appropriateness and determine compliance with practice guidelines of professional societies. Although standardized data can improve care within an individual organization, the larger impact occurs when the data are shared externally for analysis and reporting. Specifically, this standardization facilitates the extraction, transmission, and analysis of the data via registries such as the ACC NCDR. At the clinician level, the use of controlled
2. Principles of Structured Reporting

2.1. General Principles

The general principles of structured reporting in cardiovascular imaging have been published previously and remain current, relevant, and applicable. The key characteristics of a proper structured report are as follows: 1) it must be inclusive of all information relevant to both clinical care and operational administration; 2) it should be clear, concise, organized, and reproducible, as well as straightforward, to cognitively assimilate and comprehend, while being sufficiently flexible to accommodate evolutionary changes in procedures and documentation requirements; 3) it should contain all the required elements for documenting procedure indications and assessing appropriateness per local coverage determination rules and/or published AUC9-11; 4) a consistent minimum dataset should be included in the content of each report, anticipating clinical, operational, regulatory, and financial uses of the data therein; and 5) the report should be devoid of extraneous content and be brief yet thorough.
2.2. Integration of Data Acquisition With Workflow

The processes of structured reporting extend the emphasis from structure and format of the report to the integration of data acquisition with workflow, maximizing the accuracy, completeness, and efficiency of procedure report generation. In this paradigm, complete and accurate documentation occurs at every step of the workflow; the responsibility for data acquisition is shared by the entire healthcare team. Ideally, proper system design will enable this tight coupling, resulting in a final structured procedure report within minutes of procedure completion.

Typical steps that comprise a cardiovascular catheterization procedure encounter are depicted in Figure 1. In a structured reporting environment, the opportunity for data gathering begins with the request to the scheduling office. This includes requesting the capture of demographic information and procedures. Additional clinical information such as a basic history, medications, allergies, risk factors, previous procedures, and laboratory data should be available at this juncture. The idealized workflow imports (or otherwise) captures these data before the patient presents for the procedure. Ideally, data should flow bidirectionally to and from the EHR.

This basic paradigm—using optimized technology solutions to accomplish data collection by the individuals handling the data when the information becomes available—is then extended to the other steps involved in a catheterization procedure, with the data aggregated and stored for subsequent presentation and analysis (Figure 2). The need to establish specific responsibilities and accountability of the individuals for specific sets of data is an implicit step at every point in the process. No single individual is to be overburdened with responsibility. The form factor used to...
2.3. Capture of Information as Data Rather Than Prose

The first tenet of structured reporting is that the entire process requires the capture of information as discrete, defined, computable, and reusable data elements instead of dictated or typed (free text) prose. In a structured report, prose is purposefully limited to those circumstances where capture of the information as data is unwieldy or inefficient. These limited circumstances could include a brief history, details of complex procedures not otherwise adequately represented by the data, and the final impressions and recommendations. For a structured report to be successful, the permissible values of the structured data elements of the controlled vocabulary must be anticipated a priori, but the system must also have sufficient flexibility to capture ad hoc values where appropriate, because frustration can foster nonadherence and overuse of free-form data fields.

A second tenet is that all phases of data acquisition utilize the same controlled vocabulary. At a minimum, a controlled vocabulary consists of clinical data element concepts, definitions of those data elements, and notations regarding the format specific to each data type (eg, text, integer, yes/no, date/time, or alphanumeric) along with permissible (or allowed) values. Typically, data standards committees, such as the ACC/AHA Task Force on Clinical Data Standards, oversee this process on behalf of many stakeholders, with the technical representation of the data elements made available via an authoritative International Organization for Standardization 11179–compliant reference resource, such as the National Cancer Institute Enterprise Vocabulary Services system. As of the time of this publication, the data standards for catheterization procedure reporting remain a work in progress, anticipated for completion within the next several years. In lieu of a completely modeled and vetted controlled vocabulary for catheterization procedure reports, the ACC NCDR and the...
2.4. Role of the Physician in Authoring the Structured Procedure Report

A structured reporting process succeeds only if the integrity of both the structure and meaning of the data are maintained. The physician operator is primarily responsible for interpretation, description, and documentation of results and findings (ie, the “meaning” of the data). The physician also validates (and assumes responsibility for) data that others have entered throughout the sequence of events related to the catheterization. In this construct, the structure of the data is largely the province of the information technology solution used to manage the data. With all parties contributing, the procedure report is then produced automatically based upon reporting templates populated by the entirety of the data. Additionally, the data can be exported into standard (machine-interpretable) file formats such as an .xml representation, a Clinical Document Architecture (CDA) file, or a Clinical Data Interchange Standards Consortium (CDISC) file for machine-to-machine data transfer and subsequent analysis.

By shifting data collection (and data quality) responsibilities to others involved in the process of care, physician time devoted to repetitive recapture and redocumentation of data is reduced whereas a more complete set of data in the report is ensured. Optimally, this reduced workload translates into time saved, because the required responsibility for the physician operator is focused on interpretation and results documentation. Preliminary findings may even be entered by experienced catheterization laboratory staff, fellows, or Advanced Practice Practitioners (APPs) to further reduce physician operator time. Of note, the responsible physician must directly review, edit, or amend the data, an essential component of the data management system, as a well-designed and orchestrated structured reporting process will promote an accurate, efficient, and timely final catheterization report.

Because angiography is inherently visual, documentation of angiographic findings may be provided by graphical vascular tree and structural anatomy diagrams as well as by the inclusion of images in the report. The capture of these data in a graphical or image format is a highly accurate mechanism for representing angiographic findings. Although the use of a graphical vascular tree program is strongly encouraged, the specifications for vascular tree programs are beyond the scope of this document. Finally, it is recognized that there is both a paucity of data, and conflicting evidence regarding best practices in data collection and presentation. The idea that a structured report in the catheterization suite can deliver on the promises outlined in this HPS is perhaps most strongly supported by the success of the Veterans Administration Clinical Assessment, Reporting, and Tracking System for Cath Labs (CART) program. The CART program is embedded in the Veterans Administration’s EHR system and used in place of dictation and typing, following principles of the structured reporting process. Analysis of the CART system has demonstrated excellent data quality, marked improvements in timeliness in reporting, and the ability to use the data for quality improvement and registry reporting. So although the recommendations presented herein are largely based on expert consensus, the existing evidence base does support the structured reporting approach endorsed by this HPS as state of the art, evidence based, and patient centered.

2.5. The Best Practice Model

Building a best practice model for the cardiac catheterization laboratory begins with an understanding of the temporal sequence of events associated with the procedure (Figure 1) and identifying the data, systems, and individuals associated with each step of the sequence (Figure 3). Events that typically occur in the context of a catheterization procedure include the following:

1. Scheduling of the procedure
2. Preprocedure evaluation and consent by an operator or designee
3. Nursing preprocedure evaluation
4. Catheterization procedure
5. Documentation and interpretation of findings, analysis, and procedure report generation
6. Finalization and distribution of the report and report data

At the initiation of a procedure request, administrative patient data (eg, patient identifiers, demographics) are obtained from source systems such as the EHR and combined with clinical information to schedule the procedure. The IHE Cardiac Catheterization Workflow (CATH) profile integrates ordering and scheduling of cardiac catheterization procedures and ensures the accurate transfer of patient identification data. In subsequent steps, these data, coupled with other sources of information (eg, laboratory results, previous procedure findings), are further collected and again converted into data. In informatics modeling terms, actors are the individuals responsible for capturing the information, with the mechanism for capturing the information as data determined by the information systems being used by that individual. The best-practice model specifies that the form factor (eg, workstation, mobile tablet, hemodynamic monitoring station) is optimized to the actors and their respective workflows and operational logistics. A portion of the data populates subsequent downstream information systems.

Regarding the data themselves, the preprocedure evaluation, consent, and nursing preprocedure evaluation steps capture demographic, history, physical, laboratory, and medications data. The cardiac catheterization procedure utilizes these data
and adds new data: hemodynamic information, administered medications, inventory utilization, as well as angiography findings, therapeutic interventions, results, and complications. Combined with the final analysis and interpretation, report generation merges and incorporates the new data recorded, calculated, and captured during the procedure into the final structured procedure report. Catheterization reports are distributed across the enterprise for clinical care, and the data are extracted and analyzed for inventory management, process assessment, quality improvement, billing, and other administrative purposes. Combined with in-hospital and follow-up information, the data are also packaged for transmission to data registries. The IHE Cross Enterprise Document Sharing (XDS) profile exists to ensure that reports (and images) can be effectively exchanged within and between entities.30 The ultimate goal of modeling best practice in the cardiac catheterization laboratory is to explicitly identify and specify the processes, systems, and personnel that are required to interact smoothly as a coordinated entity. This creates an environment in which the interaction of the clinical team and the patient is the focus, with information and data sources available to each actor in whatever form factor will distract the least from the clinician–patient interaction. At any stage of the procedure, data are readily available to any actor, whereas data systems remain “invisible” to the actors and unobtrusive to their patient care focus. This model allows quality and process efficiency to be the primary drivers of the structured reporting process.

### 3. Catheterization Procedure Reporting: Anticipating 2 Different Reports

Although the focus of this HPS is the final (physician-authored) structured procedure report, a second complementary procedure log report is also created for each procedure via the same structured reporting process. The structured reporting process is thus designed with both of these critical reports in mind—the catheterization procedure log report and the final procedure structured report—as integrated, seamless, consistent, and intrinsic to the catheterization procedure. As a final step, both of these reports should be uploaded into the EHR system, occurring automatically once electronic signature attestation has been completed.

#### 3.1. The Procedure Log Report

The procedure log is the documentation record of the events (as time-stamped entries) occurring during a catheterization procedure, from patient entry to exit from the catheterization

---

**Figure 3.** Process–Interaction Matrix for Cardiovascular Catheterization Procedures. This chart maps the processes (across the top) that occur to accomplish a catheterization procedure and the contributions of the constituent components (left side of figure) to be coordinated with each process. Cath lab indicates catheterization laboratory; and EHR, electronic health record.
suite. Documentation of these events is the responsibility of the individual monitoring the procedure and is accomplished using the database of a hemodynamic monitoring system. Most vendors are already producing the procedure log report in a tabular (table-based) format, albeit without standardized definitions or structure. This detailed procedure log report is an integral part of the medical record, reflecting the chronological occurrence of events during a procedure.

Although there may be substantial overlap with the physician-authored procedure report, the procedure log report is constrained to the duration of the procedure, largely reflecting nursing and technologist responsibilities. As the monitoring individual transcribes events on behalf of the entire team (including the physician operator), communication among the team members is essential for accurate and complete documentation. The procedure log report should reflect the temporal occurrence of events, including documentation of the pre-procedure “time-out,” the preprocedure immediate reassessment required by The Joint Commission,31 vital signs, levels of consciousness, oxygen saturations, and other assessments and measurements performed over the course of a procedure. In addition, recording of procedural personnel, procedures performed, equipment used, medications administered, contrast volume, and radiation exposure parameters should be included. To reduce variability in the format of the data being captured, it is highly recommended that macros, drop-down lists, coded phrases, or other structured approaches be utilized in accordance with the underlying controlled vocabulary data element specifications. This practice improves both accuracy and efficiency for the monitoring recorder. Ideally, data interfaces should be implemented to automatically export data from ancillary modalities and other external equipment (eg, fractional flow reserve, intravascular ultrasound) into the procedure documentation system.

The data collected via the procedure logging process form the foundation for the procedural data section of the physician-authored structured procedure report. A degree of data transformation is needed to convert data recorded chronologically into the summary representation more appropriate for the physician-authored report. For example, a medications tally is needed in the structured procedure report, rather than a more simplistic time-stamped listing of a medication administration record. For interventions, implanted devices are associated with lesions, along with the respective device parameters (eg, stent size, maximum balloon inflation pressure); a time-stamped listing of the actual events is of much less value. As noted previously, the extraction and transformation of these data from the procedure log should be as automated as possible to reduce the workload on the physician, allowing the physician to focus on the accuracy of the documentation itself.

3.2. The Physician-Authored Structured Procedure Report

The physician-authored final catheterization procedure report fulfills the long-standing requirements for an operator-authored synthesis and summary document of the salient points of an operative or invasive procedure. In the United States, content requirements are stipulated in state and federal statutes as well as guidance provided by The Joint Commission.31 It is recommended that these content requirements (eg, documentation of indications for the procedure, procedures performed, results, complications, and recommendations; logistical, operational, and administrative information) serve as the foundation of catheterization structured reporting around the world. Of note, what is not specified by regulation is how to accomplish the specifics: whether to even use a computerized information system, the capture of data versus prose, and the format and structure of the reports themselves. This HPS fills that gap, developing the base regulatory requirements into an explicit reference standard. Specifically, Section 4 describes the specifics of the prototype formatted, tabular, structured procedure report.

Intentionally, it is recommended that the report should avoid listing the absence of a finding in certain situations. Specifically, the absence of disease in the coronary arteries (and other vascular territories) is denoted by describing the primary vessels (left main, left anterior descending, left circumflex, and right coronary artery) as “normal” without further listing the absence of pathology in the terminal branches. Conversely, when coronary disease is present, only the segments with disease are listed (ie, the term “normal” is not printed with vessels and segments free of disease). Similarly, the lack of occurrence of an adverse event is summarized by the word “none,” rather than denoting that every possible adverse event (eg, ventricular fibrillation, cardiopulmonary resuscitation, or death) did not occur. The concept of pertinent positives also extends to the listing of risk factors on the procedure report. When a risk factor is not present, the report should not list “no” (as in “no hypertension” in the patient who is normotensive). This allows the clinician to rapidly understand what is known to be abnormal while implicitly accepting as absent (or unknown) what is not otherwise mentioned or described. Of note, depending on the specifications of a secondary consumer of the data (eg, NCDR registry), there may be a requirement for acquisition of the data as either a “yes” or “no” response. Regardless of the data in the database, on the report itself, only the pertinent positives are to be listed. Although it is acknowledged that this representation is incomplete (ie, it does not differentiate negation from the absence of information), this HPS endorses “charting by exception” as a mechanism to reduce clutter and maximize readability, and because there are essentially no differences in terms of analytics among the various representations of “no” and “null.”

4. The Prototype Formatted, Tabular, Structured Procedure Report

The 2008 HPS on Structured Reporting in Cardiovascular Imaging provides a general procedure report framework for all cardiovascular imaging modalities.3 Given the additional documentation requirements for invasive and operative procedures, coupled with the variability and volume of data acquired across the spectrum of cardiovascular catheterization procedures, extensions to this general framework are necessary to handle cardiovascular catheterization reports. The need to restructure data from multiple sources into the final report, and the desire for consistency across procedures also influences this framework. These factors collectively contribute to
The rationale for the organization and formatting of catheterization procedure reports using the schema described next. A key concept is that each section of the procedure report has specific content and composition attributes that remain relatively constant from one procedure type to the next.

The final catheterization procedure report is to be organized into 3 primary sections, with each containing section-specific content (Table 1). The first section—ideally a single page of text—is an easily understood, focused summary of the salient points, that is directed to the clinical community. All clinicians (spanning the spectrum from the highly technical procedural cardiologists to nurses and other members of the clinical care team) should not need to look further than this first page to ascertain the procedures performed, diagnostic findings, and recommendations. The second section is focused on images, including a computerized depiction of the observed anatomy, findings, and results. Optionally, captured images (with or without annotations) are included in this section. Finally, the third section includes the details of the procedure. This includes administrative data, the preprocedure history (particularly information captured as structured data), most of the procedural detail, free-text descriptions of technical details, and other content relevant to the final procedure report. In addition to the content included in the published version of this HPS, additional resource information such as a sample procedure report and accompanying style guide are available in an online supplement.

4.1. Front Page Summary: Highest Value Information

The front page is explicitly intended to be a single (physical) page that contains the highest value clinical information. The purpose of this page is to communicate the key findings, interpretation, and patient care recommendations from the physician operator to the clinical care providers of the patient. The objective is for this front page summary to include all of the information needed by providers to understand the context of the procedure, what was performed, the relevant findings, and the recommendations for care. As such, it replaces (and largely mimics) the preliminary procedure note.

For all catheterization procedures, the front page summary includes the following information in the header: facility information, patient identifiers (name, date of birth, and medical record number), date of procedure, referring physician(s) and physician operator(s). In the first part of the body of the summary page, the primary indication for the procedure by International Classification of Diseases (ICD) code and a brief prose history describe the circumstances leading to the procedure. Recognizing that structured data will never substitute for the richness of language, a short description (1 to 3 sentences) of the patient’s presentation is endorsed as the most efficient mechanism to convey the clinical context. (The remaining structured data obtained during the preprocedure history and physical—such as the cardiovascular risk factors, noninvasive test findings, past procedure history, and medications—are placed in the third “report body” section). The prose history is then followed by a tabular listing of the composite procedures performed along with their corresponding CPT procedure codes.

The next section of the front page summary describes the key findings of the procedure, with the content of this section specific to the actual procedure(s) performed. This is to include vascular access site details, type and size of sheath, key hemodynamic and diagnostic findings and measurements, intervention results, and devices implanted, as well as medication and contrast totals, listed in a summary tabular format. The findings of diagnostic procedures are presented as a sequence of modular tables, listing only key findings. The complete listing of all findings is included in the third section of the report. Interventions are organized by the treatment target, which includes a listing of the equipment, implanted devices, and results in association with the target lesion. A listing of complications and estimated blood loss (or acknowledgment of the absence of complications) follows this procedure-specific information section.

4.2. Graphics and Images Section

The second section of the structured report is optional because it is dedicated to images, including graphical representations of the findings or images imported into the report. The vascular “tree” diagram should include a representation of the vascular anatomy specific to the patient, including graphics depicting vascular abnormalities, anomalies, disease, and interventions. Although vendors have developed a number of different systems to depict cardiovascular anatomy, the key criterion is the accurate depiction of the vessels in a manner that facilitates the rapid understanding of the major features of the anatomy, including the 3-dimensional relationships of key vascular structures. As such, accuracy as to the curves and squiggles of a vessel are much less important than the distribution of major and minor branches of that same vessel. Unfortunately, there is currently no unifying data schema that allows the vascular tree created by 1 vendor to be exported and reproduced by the vascular tree program of a second. It is hoped that an effort to standardize this will occur in the near future to facilitate the exchange and interoperability of graphical data. For now, the vascular tree graphics will be conveyed necessarily from provider to provider and system to system as images, rather than data. Nonetheless, the computerized graphical vascular tree representation is felt to be a critical element of the structured catheterization procedure report given its utility in communicating procedure findings and results. Similarly, a graphical description of the anatomy with structural heart disease is also a critical element. Finally, in addition to the graphical depictions generated by computerized vascular tree programs, other images can be critical to capture in the structured procedure report. These include hemodynamic tracings, angiographic still frames, ultrasound images, and other potential image types. These images are also housed in the second section of the report. Annotation of these images should be allowed.

4.3. Report Body: Details

The body (third section) of the structured procedure report contains all of the remaining data accrued during the procedure not listed on the front page summary. As nearly all of the information reproduced in the body of the report can be expected to be data, the layout of this section is a series of
Table 1. Organization of the Structured Catheterization Procedure Report

<table>
<thead>
<tr>
<th>Section 1: Summary Page</th>
<th>Section 2: Graphics and Images</th>
<th>Section 3: Report Body</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Primary Indication (ICD terminology)</td>
<td>1. Diagram (graphical tree representation) of vascular anatomy, annotated</td>
<td>1. Administrative Information</td>
</tr>
<tr>
<td>2. History</td>
<td>a. Diagnostic findings</td>
<td>Patient</td>
</tr>
<tr>
<td>a. 1-3 sentences of prose describing circumstances of the presentation</td>
<td>b. Intervention results</td>
<td>• Patient full name, date of birth, age, gender</td>
</tr>
<tr>
<td>3. Procedures (list of procedures, grouping individual procedures together by composite CPT code)</td>
<td>a. Hemodynamic tracings</td>
<td>• Race, ethnicity</td>
</tr>
<tr>
<td>4. Procedure details</td>
<td>b. Images +/- annotations (embedded at a reduced resolution, with reference to DICOM image)</td>
<td>• Insurance</td>
</tr>
<tr>
<td>a. Vascular access site(s)</td>
<td>2. Image capture</td>
<td>• Medical record number</td>
</tr>
<tr>
<td>i. Sheath size, sheath status at end of procedure, vascular closure method</td>
<td>a. Hemodynamic tracings</td>
<td>• Case accession number (or other unique study ID)</td>
</tr>
<tr>
<td>b. Catheters [diagnostic imaging / guide catheters]</td>
<td>b. Images +/- annotations (embedded at a reduced resolution, with reference to DICOM image)</td>
<td>Healthcare Facility</td>
</tr>
<tr>
<td>i. Diagnostic</td>
<td>3. Procedures (list of procedures, grouping individual procedures together by composite CPT code)</td>
<td></td>
</tr>
<tr>
<td>ii. Intervention</td>
<td>a. Vascular access site(s)</td>
<td>• Complete facility information: name of healthcare entity, catheterization location (laboratory), address, FAX number, phone number, laboratory accreditation</td>
</tr>
<tr>
<td>c. Diagnostic findings [&quot;Box 1&quot; on sample report – see Table 2 for details]</td>
<td>4. Procedure details</td>
<td>Operator, Staff</td>
</tr>
<tr>
<td>i. Findings, hemodynamics, calculations</td>
<td>a. Vascular access site(s)</td>
<td>• Referring Providers</td>
</tr>
<tr>
<td>d. Interventions [&quot;Box 2&quot; on sample report – see Table 2 for details]</td>
<td>b. Catheters [diagnostic imaging / guide catheters]</td>
<td>• Primary care provider</td>
</tr>
<tr>
<td>i. Interventions [&quot;Box 2&quot; on sample report – see Table 2 for details]</td>
<td>i. Diagnostic</td>
<td>• Cardiologist</td>
</tr>
<tr>
<td>5. Adverse Events</td>
<td>ii. Intervention</td>
<td>• Reason for request (ideally, replica of information received via EHR)</td>
</tr>
<tr>
<td>6. Medication and Contrast Totals</td>
<td>a. Hemodynamic tracings</td>
<td>• Procedure requested, date of request</td>
</tr>
<tr>
<td>7. Impressions</td>
<td>b. Images +/- annotations (embedded at a reduced resolution, with reference to DICOM image)</td>
<td>• Requestor</td>
</tr>
<tr>
<td>a. Prose listing of summary findings</td>
<td>2. History and Physical</td>
<td>Encounter Category</td>
</tr>
<tr>
<td>b. Prose listing of care recommendations</td>
<td>i. Symptom class</td>
<td>• Elective, urgent, emergency, salvage (and subcategories)</td>
</tr>
</tbody>
</table>

Table 1. Continued

- Family history (pertinent positives only)
- Previous procedures and previous events, with pertinent results
- Allergies and sensitivities
- Physical examination (limited)
- Laboratory values (limited: BMP, WBC, Hgb, Hct, platelet, PT, INR, PTT)
- Procedure indications (ICD terminology)

3. Procedure
- Individual (component) procedures performed (as CPT codes, or using other standardized procedure terminology – these are not the aggregate procedures reported on the summary page)
- Logistics (time in, time out, consent/medication administration)
- Starting vital signs: BP, pulse
- Access site (location(s), sheath(s) size and manufacturer, brand, other sheath information); sheath disposition at end of case
- Vascular hemostasis method
- Anesthesia support (if applicable)
- Surgical support (if applicable)
- Hemodynamic support (if applicable)
- Type of support: when initiated (eg, elective at the start of the case, planned for the case, urgent in response to a complication), and disposition at end of case

4. Diagnostic Findings
- Diagnostic findings (organized by anatomic structure or physiologic function) ["Box 3" on sample procedure report – see Table 3 for details]
- Equipment
- Hemodynamic measurements, calculations (plus reference to DICOM Hemodynamics Report if applicable)
- Angiography findings, interpretations (plus reference to DICOM Quantitative Analysis Report if applicable)

5. Intervention (grouped by anatomic target, if multiple lesions treated)
- Equipment
- Baseline anatomy
- Devices deployed, device deployment parameters
- Procedure notes

6. Summaries
- Medications in-lab (time-stamped)
- Drips running at completion of case (if applicable)
- Contrast type and total
- Radiation exposure (fluoroscopy time, dose area product, cumulative air kerma, reference to DICOM Dose Report)
- Estimated blood loss
- Specimens removed
- Final ICD diagnoses
- Final procedure notes

BMP indicates basic metabolic profile; BP, blood pressure; CPT, current procedural terminology; DICOM, Digital Imaging and Communications in Medicine; EHR, electronic health record; Hct, hematocrit; Hgb, hemoglobin; ICD, implantable cardioverter defibrillator; INR, international normalized ratio; PT, prothrombin time; PTT, partial thromboplastin time; and WBC, white blood cell count.

Structured, formatted tables. In sequential order, the information in the body is included in the following subsections.

4.3.1. Administrative Information

The capability of information systems to meaningfully interoperate requires context, starting with the administrative data uniquely identifying the patient and procedure. Accuracy along with the ability to share data across systems is critical, not only for clinical care, but also for supply chain management, billing, laboratory administration, quality assessment, and performance and outcomes analyses. Patient demographics provide personal information and...
unique patient identifiers to link the patient to the report. Demographic elements include the full name of the patient at the time of the procedure, medical record number, date of birth, gender, and race. All of these should be included to provide sufficient information to correct errors and to allow comparison of data over time and across providers. Special care must be taken in the identification of fetal and newborn patients, as names and other identifiers may change following birth. Insurance information or other payer information may be included. In most healthcare organizations, all of these data are available electronically through the relevant admission-discharge-transfer and order management data streams, and it is highly recommended that these data streams be used to initialize and populate the catheterization laboratory modality, hemodynamic, and procedure reporting systems. Populating these systems with data from the hospital database limits errors and facilitates bidirectional information interchange.

Information identifying the healthcare organization, laboratory, operators, and staff are key administrative data included in this section of the body of the report. The facility name, address and other contact information, and the specific laboratory (if there are multiple laboratories in the facility) are noted. Accreditation status and entity are included, given the increasing importance of accreditation of cardiac catheterization laboratories. Along with the physician operator, the report lists the names and identifiers of all individuals involved in the study, including the names and credentials of the nurses, technologists, APPs, trainees, and all others involved in the performance of the procedure. The list of referring providers, consisting of not only the requestor of the procedure, but also the primary care and referring cardiologist, facilitates distribution of the final report.

An objective of the HITECH Act of 2009 is to improve communication of the specifics of consultation requests, and the catheterization procedure environment presents a prime opportunity to leverage the functionalities being added to EHR systems to fulfill this objective.15 A fully formed EHR procedure request describes the clinical situation, question, and study indication, as well as identifies the provider requesting the procedure. The request also includes the date and time of the order, study priority (elective, urgent, or emergency), and special handling instructions such as a callback number. Inclusion of this study referral information should be anticipated for the near future as these data become electronically available by direct data transfer.

4.3.2. History and Risk Factors
Two complementary sets of history information are to be captured for documentation purposes. As described in Section 4.1, because the complexities and nuances of patient history are unlikely to be adequately conveyed using a structured data construct, a brief sentence history (1 to 3 sentences) is to be included on the front page summary. However, this analog history is largely unusable for purposes other than human cognitive interpretation. This necessitates the structured capture of key elements of the history (typically the class of symptoms, including limited details regarding the acuity of those symptoms) along with risk factors, medications, and previous procedures. The structured data are to be included in the body of the report. As data, these elements are used in coverage determinations as well as in the assessment of appropriateness per the relevant AUC and other practice guideline recommendations for invasive and interventional procedures. Of note, AUC criteria are being developed for additional procedures, which will expand the requirements for the collection of history and risk factor information as data.

Historical data are typically first available from the referring physician requesting the procedure. Personnel involved in the scheduling of procedures are positioned to capture this data, with those on the clinical team evaluating the patient prior to catheterization (particularly APPs or the actual physician operator) then being in the position to confirm and validate these data. Although some translation may be required (eg, free-text information found in the EHR), the ideal workflow accommodates even this issue by having all individuals upstream of the actual procedure participate in the process of converting information into data.

4.3.3. Procedure Details
The capture of procedure details is largely the responsibility of the laboratory nursing and technologist staff. From the time of laboratory entry to departure, all relevant events are to be captured in a time-stamped log, typically via the hemodynamic monitoring system of the laboratory. This includes the component parts of the procedure as it is being performed, patient status and hemodynamics, names and doses of medications, observations and measurements, and other pertinent actions and events.

The conversion of the events from a time-stamped log database structure into the format of a structured report requires summarization and transformation of that data. This post-processing necessarily impacts database design, because the database must support direct data conversion, preferably in real time. Aside from the medication log, a time-stamped log of the other events is generally not useful in the final procedure report. Instead, the information is arranged in a fashion that makes the most clinical sense, grouping and organizing related information in a clinically cogent manner. This applies to the detailed list of the individual (component-level) procedures performed, logistics, consent and other required documentation, vascular access and disposition, details regarding ancillary hemodynamic support, total volume and name of contrast agent(s), radiation exposure parameters (fluoroscopy time, cumulative air kerma, and dose-area product), as well as intraprocedural findings, measurements, observations, and results. In this paradigm, data entered by staff into the documentation system are converted from individual time-stamped line items into aggregate information ready for the final (physician-authored) structured procedure report. Done properly, the summary data are directly imported into the structured procedure report without further physician processing or handling. This in turn further reduces the time required of the physician to review the data and complete the final report. To improve patient safety, the cumulative contrast volume and radiation dose for all diagnostic and interventional procedures should be recorded and incorporated into the electronic medical record as readily accessible data elements.
4.3.4. Diagnostic Results
Study findings will vary substantially depending on the study performed, and therefore, specifics by procedure are covered in much greater detail in the sections to follow (Table 2). At a general level, for the reporting of procedure results, the layout paradigm common to the diagnostic results section is to group all quantitative measurements, qualitative assessments, and calculated data with a given anatomic structure and/or physiological function, beginning the grouping with an appropriate label. For example, under a header of “left ventricle,” the findings include left ventricular size, dilation, ejection fraction, segmental wall motion, and end-diastolic pressure. Groupings are presented successively in a logical anatomic or physiological sequence established by the conventions of medicine. Measurements should be properly referenced to norms for body size, gender, and age. Abnormal or inappropriate physiological and hemodynamic changes observed during the procedure, whether spontaneous or in response to stress or other interventions, are also included. Reported data should be based upon standardized data elements for anatomic, morphological, physiological, and functional findings as developed and recommended by relevant data standards groups.

4.3.5. Intervention
Similar to the diagnostic results section, the intervention section will vary substantially depending on the procedure performed (Table 3). A dedicated section for interventions explicitly separates diagnostic components from interventional procedures, with reporting in the intervention section organized by the anatomic treatment target of the intervention. The common layout paradigm of the intervention section is to describe the treatment target first, followed by the equipment used, parameters of that equipment, and the results of the intervention. Pre- and postprocedure results are described in sufficient detail to determine procedure success or failure. Because free-text notes are occasionally needed to further characterize the intervention, a limited free-text section (a few sentences) may be associated with each treatment target. Again, the specific data to be reported by procedure are covered in much greater detail in the sections to follow.

4.3.6. Final Diagnoses
With respect to the interpretation of the results and the final recommendations thereof (impressions and recommendations), this set of information is included on the summary (front) page. As described previously, the relatively short impressions and recommendations sections on the summary page are concise free-text descriptions of the findings, comparison to prior studies (where applicable), impressions and conclusions, immediate care recommendations, and the long-term management plan. The original question for which the study was performed should be explicitly answered.

In the final diagnoses section of the report body, a list of the ICD-encoded diagnoses reflecting the final interpretation of the procedure is included (largely for billing and regulatory purposes). Although discouraged, if a traditional dictated note is created, it is included at the end of the body of the structured report.

Table 2 Diagnostic Procedures Report Content. For each procedure, the content listed under the header “Summary Page” corresponds to content placed in Box 1 on the prototype report. Content listed under the header “Details Section” corresponds to content placed in Box 3 on the prototype report

<table>
<thead>
<tr>
<th>Diagnostic: Right/Left Heart Catheterization</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Summary Page</strong></td>
</tr>
<tr>
<td>Right heart cath</td>
</tr>
<tr>
<td>RA mean</td>
</tr>
<tr>
<td>RV systolic, diastolic, EDP</td>
</tr>
<tr>
<td>PA mean</td>
</tr>
<tr>
<td>PCW mean</td>
</tr>
<tr>
<td>AV O2 diff</td>
</tr>
<tr>
<td>Cardiac output, cardiac index</td>
</tr>
<tr>
<td>QpQs [only if not 1.0]</td>
</tr>
<tr>
<td>PVR, SVR</td>
</tr>
<tr>
<td><strong>Details Section</strong></td>
</tr>
<tr>
<td>Right heart / right/ left heart catheterization</td>
</tr>
<tr>
<td>1. Assessment conditions: baseline/rest; [challenge with vasoactive agent]</td>
</tr>
<tr>
<td>a. Patient height, weight, BSA</td>
</tr>
<tr>
<td>b. Patient blood pressure, heart rate</td>
</tr>
<tr>
<td>c. Inspired O2:</td>
</tr>
<tr>
<td>d. Vasoactive agent [intravenous vasodilator, inhaled vasodilator, vasopressor, inotrope]:</td>
</tr>
<tr>
<td>2. Oxygen saturation (%)</td>
</tr>
<tr>
<td>a. Innominate</td>
</tr>
<tr>
<td>b. SVC</td>
</tr>
<tr>
<td>c. IVC</td>
</tr>
<tr>
<td>d. RA</td>
</tr>
<tr>
<td>e. RV</td>
</tr>
<tr>
<td>f. MPA</td>
</tr>
<tr>
<td>g. LPA</td>
</tr>
<tr>
<td>h. RPA</td>
</tr>
<tr>
<td>i. LA</td>
</tr>
<tr>
<td>j. Pulm vein</td>
</tr>
<tr>
<td>k. LV</td>
</tr>
<tr>
<td>l. Asc ao</td>
</tr>
<tr>
<td>m. Desc ao</td>
</tr>
<tr>
<td>3. Pressures (mm Hg)</td>
</tr>
<tr>
<td>a. Hepatic wedge: mean</td>
</tr>
<tr>
<td>b. RA: a wave, v wave, mean</td>
</tr>
<tr>
<td>c. RV: systolic/diastolic, end diastolic</td>
</tr>
<tr>
<td>d. MPA: systolic/diastolic, mean</td>
</tr>
<tr>
<td>e. RPA: systolic/diastolic, mean</td>
</tr>
<tr>
<td>f. LPA: systolic/diastolic, mean</td>
</tr>
<tr>
<td>g. RPCW: a wave, v wave, mean</td>
</tr>
<tr>
<td>h. LPCW: a wave, v wave, mean</td>
</tr>
<tr>
<td>i. LV: systolic/diastolic, end diastolic</td>
</tr>
<tr>
<td>j. Asc ao: systolic/diastolic, mean</td>
</tr>
<tr>
<td>k. Desc ao: systolic/diastolic, mean</td>
</tr>
<tr>
<td>4. Pressure gradients [specify mean/peak-peak/or both] (mm Hg)</td>
</tr>
<tr>
<td>a. PCW-PA</td>
</tr>
<tr>
<td>b. RPA-MPA</td>
</tr>
<tr>
<td>c. LPA-MPA</td>
</tr>
<tr>
<td>d. MPA-RV</td>
</tr>
<tr>
<td>e. RV inflow-RV outflow</td>
</tr>
<tr>
<td>f. RV-RA</td>
</tr>
<tr>
<td>g. RA-hepatic wedge</td>
</tr>
<tr>
<td>h. LA-LV diastolic</td>
</tr>
<tr>
<td>i. LV inflow-LV outflow</td>
</tr>
<tr>
<td>j. LV-Asc ao</td>
</tr>
<tr>
<td>k. Asc ao-Desc ao</td>
</tr>
<tr>
<td>5. Calculations</td>
</tr>
<tr>
<td>a. Hemoglobin: gm/dL</td>
</tr>
<tr>
<td>b. O2 consumption: mL O2/min</td>
</tr>
</tbody>
</table>

(Continued)
Table 2. Continued

c. C0 [method]: L/min
d. Cl: L/min/m2
e. AV02 diff: vol%
f. Qp: L/min
g. Qp index: L/min/m2
h. Qs: L/min
i. Qs index: L/min/m2
j. Qp:Qs
k. PVR: Wood units [or] dynes-sec/cm
l. SVR: Wood units [or] dynes-sec/cm
m. Valve area by [method]: cm2

Diagnostic: Congenital Disease Angiography

Summary Page
Angiography of [structure]: summary findings

Details Section (table)
Structure	 Catheter	 Angles	 Findings
RA angiogram
Right ventriculogram
MPA angiogram
RPA angiogram
LPA angiogram
RPAW angiogram
LPAW angiogram
LPAH angiogram
Left ventriculogram
Ascending aortogram
Descending aortogram
Other angiogram [specify location, eg, MAPCA, decompressing vein, collaterals]

Diagnostic: Left Heart Cath/Left Ventriculography/Aortography

Summary Page
Pressures:
Aorta: systolic/diastolic, mean
Left ventricle: systolic/diastolic, LVEDP
Left ventriculogram
Ejection fraction
LV segmental wall motion: [abnormal only; if none, then “normal”]
Mitril regurgitation: [grade]
Other findings: [describe]

Details Section
Pressures:
Aorta: systolic/diastolic, mean
Left ventricle: systolic/diastolic, LVEDP
Left ventriculogram
Ejection fraction
LV segmental wall motion: [table of all segments per the
5 segment model]
RAR includes anterior, apical, inferior; LAD includes septal,
posteroanterior segments
Mitril regurgitation: [grade]
Other findings: [describe]

Aortogram
Findings: [describe]

Diagnostic: Coronary Arteriography

Summary Page
Pressures:
Aorta: systolic/diastolic, mean
Coronary angiography (summary findings)
Dominance: [if not right dominant]
Left main: [normal, insignificant, or list of significant lesions]
Left anterior descending: [normal, insignificant, or list of significant lesions]

| Left circumflex: [normal, insignificant, or list of significant lesions] |
| Right coronary: [normal, insignificant, or list of significant lesions] |
| Number of diseased vessels: [0, 1, 2, 3] |

Graft angiography
Number of grafts (origins)
Number of distal anastomoses placed
Number of distal anastomoses patent
Significant graft lesions

Details Section
Coronary angiography (table)
Dominance
Artery-segment (size) % stenosis	 Descriptors	 TIMI flow
Graft angiography (table)
Graft type-anastomosis Segment % stenosis	 Descriptors	 TIMI flow
Adjunctive diagnostic assessment (table)
Modality Segment Findings
[FFR] [IVUS] [OCT]

Diagnostic: Peripheral Arteriography

Summary Page
Peripheral vascular angiography (summary findings)
[Vessel/segment]: [normal, insignificant, or list of significant lesions]
Graft angiography: [normal, insignificant, or list of significant lesions]
Number of diseased leg vessel segments: [based on aorto-iliac,
femoro-popliteal, and tibial-cral segmentation schema]

Details Section
Number of diseased leg vessel segments: [based on aorto-iliac,
emoro-popliteal, and tibial-cral segmentation schema]
Peripheral vascular angiography (table)
Artery-segment % stenosis	 Lesion type
Graft angiography (table)
Graft type-anastomosis Segment % stenosis	 Lesion type
Adjunctive imaging (table)
Modality Segment Findings
[IVUS] [OCT]

Diagnostic: Cerebrovascular Arteriography

Summary Page
Aortic arch type
Cerebrovascular angiography (summary of lesions in injected arteries):
[normal, insignificant, or list of significant lesions]

Details Section
Aortic arch type (ie Types 1-3, bovine)
Hemispheric cross-filling
Cerebrovascular angiography (table)
Artery-segment % stenosis	 Lesion type
ASC ao indicates ascending aorta; AV O2 diff, arteriovenous oxygen difference;
BSA, body surface area; Desc ao, descending aorta; EDP, end diastolic pressure;
FFR, fractional flow reserve; IVC, inferior vena cava; LA, left atrium; IVUS,
intravascular ultrasound; LAD, left anterior oblique; LPA, left pulmonary artery;
LPAW, left pulmonary artery wedge; LPCW, left pulmonary capillary wedge;
LV, left ventricle; LVEDP, left ventricular end diastolic pressure; MAPCA, major
aortopulmonary collateral artery; MPA, main pulmonary artery; OCT, optical
coreherence tomography; PA, pulmonary artery; PCW, pulmonary capillary wedge;
PVR, pulmonary vascular resistance; QP/Qs, pulmonary systemic flow ratio; RA,
right atrium; RAO, right anterior oblique; RPA, right pulmonary artery; RPAW,
right pulmonary artery wedge; RPCW, right pulmonary capillary wedge; RUPV,
right upper pulmonary vein; RV, right ventricle; SVC, superior vena cava; and SVR,
systemic vascular resistance.
### Table 3. Intervention: Coronary Artery Disease

**Summary Page**
- PCI of [coronary segment]
- Devices: [type(s) of interventions – eg balloon angioplasty, atherectomy, stent implantation, aspiration thrombectomy, etc.]; stent-brand name, diameter × length, bare metal or drug-eluting, UDI; final balloon if no stent
- Results: pre % stenosis to post % stenosis [pre TIMI flow to post TIMI flow, if either abnormal (ie, not TIMI 3); no reflow]

**Details Section**
- PCI of [coronary segment]
- Intervention:
  - Guide catheters: manufacturer, Fr size, model
  - Guide wires: manufacturer, diameter, model
  - Devices: balloons – timing (pre versus post stent implantation), diameter × length, max pressure × duration; other devices – with parameters; stent – manufacturer, brand name, diameter × length, max pressure × duration, bare metal or drug-eluting, UDI
- Results: pre % stenosis to post % stenosis [pre TIMI flow to post TIMI flow, if either abnormal (ie, not TIMI 3)]

### Table 3. Continued

**Intervention: Transcatheter Aortic Valve Replacement (TAVR)**

**Summary Page**
- Intervention: valve – manufacturer, brand name, size; de novo or valve in valve
- Results: mean gradient pre to mean gradient post; regurgitation post – grade and location (paravalvular, central)

**Details Section**
- Angiography
  - a. Femoral artery angiogram: RFA/LFA, findings
  - b. Ascending aorta angiogram: findings
- Aortic valve-baseline
  - a. Previous aortic valve bioprosthesis (make and size)
  - b. Dimensions by [CT/MR/echo]
    - Annulus (mm):
    - Sinus segment (mm):c. Hemodynamic assessment
  - LV pressure
  - Asc aorta pressure
  - Peak-peak gradient, mean gradient
  - Valve area by [method]:
    - Measurement condition: resting/inotrope and dose

**Intervention**
- a. RV pacing
  - Rate:
    - Timing: (when pacing used during procedure)
- b. Balloon aortic valvuloplasty:
  - Guide wire: manufacturer, diameter, model
  - Balloon – manufacturer, brand name, diameter × length
  - Inflation duration (sec):
  - Inflation pressure (atm):
  - c. Transcatheter aortic valve replacement
  - Valve system – manufacturer, brand name, size
  - De novo or valve in valve
  - d. Maldeployment – present or absent; if present:
    - Valve embolization: LV or aortic
    - Management: open conversion, deployment in desc thoracic ao
- Results:
  - a. Hemodynamic assessment
  - LV pressure
  - Asc aorta pressure
  - Peak-peak gradient, mean gradient
  - Valve area by [method]:
    - Measurement condition: resting / inotrope and dose
  - b. Ascending aorta angiogram:
    - Paravalvular regurgitation: [none, 1+, 2+, 3+, 4+]
  - c. Iliac/femoral artery angiogram: findings
  - d. Transesophageal echocardiogram
    - Paravalvular regurgitation: [none, 1+, 2+, 3+, 4+]
    - Central regurgitation: [none, 1+, 2+, 3+, 4+]

**Access Site Closure**
- a. Closure method: open surgical, closure device – manufacturer, brand name
- b. Angiogram: findings
- c. Crossover technique
  - Sheath used – manufacturer, brand, size; balloon used – manufacturer, brand, size

**Intervention: Congenital Stenosis**

**Summary Page**
- Target: RPA, LPA, Coarctation, other stenosis [specify lesion]
- Devices: [type(s) of interventions – eg balloon angioplasty, stent implantation]; stent - brand name, diameter × length, bare metal or covered, UDI
- Results: gradient pre to gradient post; MLD pre to MLD post

(Continued)
### Table 3. Continued

<table>
<thead>
<tr>
<th>Details Section</th>
<th>Intervention: Valvuloplasty</th>
</tr>
</thead>
<tbody>
<tr>
<td>Target: aortic valve, mitral valve, pulmonic valve, tricuspid valve; annulus diameter</td>
<td>Summary Page</td>
</tr>
<tr>
<td>Devices: final balloon – diameter × length</td>
<td>Results: gradient pre to gradient post; MLD pre to MLD post</td>
</tr>
<tr>
<td>Details Section</td>
<td>Technical notes (analog text)</td>
</tr>
<tr>
<td>Target: aortic valve, mitral valve, pulmonic valve, tricuspid valve; annulus diameter</td>
<td>Intervention: Defect Closure</td>
</tr>
<tr>
<td>Devices: balloons – timing (pre versus post stent implantation), diameter × length, max pressure × duration; other devices – with parameters; stent – manufacturer, brand name, diameter × length, max pressure × duration, bare metal or covered, UDI</td>
<td>Summary Page</td>
</tr>
<tr>
<td>Results: gradient pre to gradient post; MLD pre to MLD post</td>
<td>Details Section</td>
</tr>
<tr>
<td>Target: ASD, PDA, VSD, other defect [specify defect]</td>
<td>Intervention: Cardiac Biopsy</td>
</tr>
<tr>
<td>Devices: closure device - brand name, size, UDI</td>
<td>Details Section</td>
</tr>
<tr>
<td>Result: successful closure, unsuccessful closure</td>
<td>Summary Page</td>
</tr>
<tr>
<td>Device: final balloon – diameter × length</td>
<td>Details Section</td>
</tr>
<tr>
<td>Target: ASD, PDA, VSD, other defect [specify defect]</td>
<td>Intervention: Cardiac Catheterization (Right, Left, Coronary Intervention)</td>
</tr>
<tr>
<td>ASD characteristics:</td>
<td>4.4.1. Cardiac Catheterization (Right, Left, Coronary Intervention)</td>
</tr>
<tr>
<td>ASD type:</td>
<td>The hemodynamic data acquired during right heart cardiac catheterization provides an assessment of cardiac performance along with the physiological impact of a number of cardiac structural abnormalities. Data imported from a hemodynamic monitoring system must be easily edited and corrected in the reporting system. Critically, despite advances in the computerized algorithms for automated detection and measurement</td>
</tr>
<tr>
<td>Size by echo (mm):</td>
<td>(Continued)</td>
</tr>
</tbody>
</table>
of hemodynamics, all data obtained during a right heart catheterization should not just be accepted as an import or pass-through from the hemodynamic recording system but must be reviewed, verified, and corrected by the physician operator. Substantive discrepancies between what is automatically determined by the hemodynamic recording system and more relevant measurements identified manually by the physician operator can be present and result in major errors of interpretation or incomplete conclusions.

An extensive set of data can be acquired during a right heart catheterization, particularly if a shunt run is performed, an assessment of a therapeutic intervention is conducted (eg, nitric oxide challenge, exercise, volume challenge, intra-aortic balloon pump placement), or a structural defect is present. Right heart catheterization results to be reported on the summary page should reflect the key findings, focusing on mean filling pressures, pulmonary pressures and resistance, cardiac performance (cardiac output and index), responses to intervention (if conducted), and summary calculations (eg, valve area or shunt magnitude). On the other hand, the complete set of data, such as the fraction of inspired oxygen (Fio₂), end-expiration phasic pressures, oxygen content and saturations measurements, dose of nitric oxide administered, and formal calculations are to be reported in the report body section. In the evaluation of restrictive cardiomyopathy, constriction, and valvular abnormalities, the qualitative and quantitative assessment and comparison of multiple simultaneous waveforms is to be reported, including pertinent negatives. On the summary page, the findings are to be reported in the interpretation section, with representative tracings included in the second (graphics and images) section that support the qualitative interpretation of the waveforms.

Although the formal term “left heart” catheterization implies placement of a catheter in the left ventricle, the more generic concept of left heart catheterization includes coronary angiography, left ventriculography, and transvalvular hemodynamics for the assessment of valvular abnormalities. The summary page is to convey a sufficient amount of information for the clinician to understand the anatomy visualized during left heart catheterization. This includes a notation regarding the number of diseased vessels, coronary dominance, coronary anomalies, and summary findings related to bypass graft anatomy. Optionally, a listing of the hemodynamically significant lesions organized by coronary (or graft) segment location can be listed on the summary page. If left heart catheterization is performed, left ventricular end-diastolic pressure (LVEDP) and mean aortic valve gradient (if a gradient is present) should be reported on the summary page. If left ventriculography is performed, the ejection fraction and mitral regurgitation grade should also be reported on the summary page.

The complete details of left heart catheterization are to be reported in the third (report body) section, including a description of the coronary anatomy and branches, dominance, anomalies, a listing of all coronary lesions with corresponding anatomic location, and additional qualitative terms that further describe the extent and type of disease. Of note, the reporting of coronary disease is by exception—reporting of “0% stenosis,” “no disease,” or other similar approaches denoting the absence of disease is of no real utility and increases clutter. The simultaneous hemodynamic measurements of the aorta and left ventricle are reported, including peak-peak and mean differences between pressure measurements. For left ventriculography, in addition to the ejection fraction, regional wall motion is described as normal, hyperkinetic, hypokinetic, akinetic, or dyskinetic by specific wall segment. Quantitative regurgitant volume or percent by volumetric analysis of the left ventriculogram versus forward cardiac output is included (and labeled as such) if performed. Other observations such as calcification and other findings are reported in sufficient detail to meaningfully contribute to the overall interpretation of the study.

Key data reported regarding PCI include identification and description of the lesion(s), equipment used, equipment parameters (eg, balloon type and nominal balloon diameter, stent type, nominal stent diameter and length, maximum inflation pressures), technical details if exceptional (eg, retrograde crossing of a chronic total occlusion) along with the angiographic results. On the summary page, this information is concatenated into a single line of text, listing the lesion, stent information, notation of the type of intervention if stent implantation is not performed, and the pre and post results. In the report body section, parameters associated with each device are recorded. If an invasive evaluation is performed of an intermediate lesion, the details of the findings are reported. In the case of fractional flow reserve, the specific value should be reported along with the coronary segment(s) interrogated. Similar results from intravascular ultrasound, including intraluminal diameter, extent of calcification, evidence of prior stent placement, and presence or absence of dissection or thrombus, are listed. The current role for optical coherence tomography is unclear, but if performed, pertinent findings should be described in detail.

4.4.2. Peripheral Vascular Catheterization

The performance of peripheral vascular catheterization often requires different techniques, tools, and implantable devices from those required for cardiac catheterization. The scope of this HPS covers peripheral vascular procedures for atherosclerotic occlusive disease. Thus, renal, aorto-iliac, femoro-popliteal, and tibial catheterization and intervention are included. Endovascular aneurysm repair of the thoracic aorta, endovascular aneurysm repair of the abdominal aorta, and all venous procedures (inferior vena cava filters, thrombolysis for deep vein thrombosis, venous intervention, etc.) are purposefully not modeled via this initiative, although extensions to include these procedure types may be added in the future.

The history, physical, and vascular anatomic descriptions for peripheral vascular disease reporting are target-lesion specific; use of the anatomic lexicon published by the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Clinical Data Standards for Peripheral Atherosclerotic Vascular Disease) or the TransAtlantic Inter-Society Consensus is recommended. Vascular access for peripheral catheterization is much more varied than for cardiac catheterization and can include femoral retrograde, femoral antegrade, brachial, axillary, radial, popliteal, and other access
sites. As with cardiac catheterization, the summary page is to convey summary information sufficient for the clinician to understand the approach used and the anatomy visualized. For lower extremity disease, analogous to coronary disease, this includes notation regarding the “number” of diseased vessels per leg, using aorto-iliac, femoro-popliteal, and tibial-crural groupings as equivalents to the coronary concept of a “vessel,” along with summary findings of bypass graft anatomy. This section can optionally include a listing of hemodynamically significant lesions. A summary of interventions and results is included, patterned after the approach used for the reporting of coronary interventions.

In the report body, the anatomy visualized is matched with the specific diagnostic catheter type and shape. The findings of arteriography are reported via a formatted table, inclusive of lesion segment location, maximum percent stenosis, and qualitative descriptors of the disease where appropriate. If abnormal, the condition of previously deployed devices (eg, migrated, fractured, stenosed) is described. The details of endovascular intervention including the technique for crossing a lesion (true lumen versus subintimal or 0.035” versus 0.014” wire, recanalization adjuncts), and the sequence, types, and parameters of endoluminal treatment (eg, balloon size, length, dilation pressures) are listed. Alternative endoluminal treatments are noted (eg, plaque debulking, atherectomy, cryoplasty, scoring balloon thrombolysis). When a stent is deployed, the stent type (eg, balloon-expandable versus self-expanding) and size parameters are listed in conjunction with the target lesion and the final residual percent stenosis.

4.4.3. Cerebrovascular Catheterization

Catheterization of the cerebrovasculature includes the aortic arch, brachiocephalic branches, carotid, and vertebral artery territories. The scope of this HPS covers cerebrovascular procedures for atherosclerotic occlusive and other types of obstructive disease, and specifically excludes intracranial disease, including aneurysms. Imaging and intervention of intracranial arteriovenous aneurysm, fistula, and venous anatomy are not modeled in this initiative, although extensions to include these procedure types may be added in the future.

Given the variability of anatomy of the vessels of the aortic arch, the actual arch and great vessel anatomy are documented on the front page summary as are the specialized catheters required to study the cerebrovasculature. Similar to the cardiac and peripheral vascular catheterization use cases above, description of cerebrovascular intervention should be displayed as a single concatenated line of text, listing the lesion, stent data, notation of the type of intervention if stent implantation is not performed, and the pre and post results.

Full details of the cerebrovascular catheterization procedure are to be included in the report body. In addition to documentation of vascular disease—for extracranial and intracranial imaging—the carotid system, cerebral system, Circle of Willis and cross-filling of hemispheric blood flow are described. For carotid stenting, the time interval between the deployment of an embolic protection device in the internal carotid artery and the carotid intervention is noted in addition to the standard documentation regarding the equipment used, devices deployed, and the parameters thereof.

4.4.4. Valvular Heart Disease: Transcatheter Aortic Valve Replacement

TAVR for the treatment of severe symptomatic aortic stenosis has been shown to be a viable therapy for patients deemed at high or extreme risk for conventional surgical aortic valve replacement (AVR). As a result of the complexity of these patients and their significant medical comorbidities, the concept of the multidisciplinary heart team (MHT) has been accepted and embraced by the respective professional societies. Furthermore, the complexity of the cases and the requirement of the expertise of the multiple specialties have resulted in the general acceptance that these procedures should be performed in a hybrid operating room/catheterization laboratory setting, with full and engaged participation of the entire MHT. Therefore, the structured procedure report must reflect this genuine multispecialty collaboration among the subspecialties.

On the Front Page Summary, vascular access information, anesthesia, circulatory support, and a summary of the TAVR procedure and results (concatenated preprocedure stenosis severity, device implanted, and final result) are listed. However, most of the actual data of a TAVR procedure are reported in the report body (Table 3). This begins with a listing of all of the physicians and healthcare providers contributing to the performance of the TAVR procedure, including anesthesiologists, neurologists, sonographers, and other imaging specialists, nurses, and technologists. As recently mandated by the coverage decision of the US Centers for Medicare and Medicaid Services, at least 1 surgeon and 1 interventional cardiologist must be present for the procedure. These individuals (and their respective specialties) are identified as the operators of the procedure.

Data in the report history to substantiate the decision of the MHT to perform TAVR instead of surgical AVR are listed as discrete data elements. The rationale for TAVR, however, is documented for each patient via the free-text history on the front page summary.

From a procedural standpoint, routes of vascular access (ie, transfemoral, transapical, transaortic, or subclavian), as well as the method of access (ie, percutaneous, surgical cutdown, or vascular conduit), for TAVR are documented in the respective sections of both the summary page and procedure details section. For percutaneous access, the type and number of closure devices used are also listed. For surgical cutdown, the location of the incision is listed.

If right heart catheterization is performed, the data are reported as described in the right heart catheterization section above. Specifics related to positioning and rapid ventricular pacing are captured as data. At the completion of deployment, the final TAVR positioning, function of the prosthesis, and evidence of paravalvular leak are essential data of the report.

Complication management and bailout maneuvers are often required in TAVR procedures. If cardiopulmonary bypass is required for hemodynamic support, duration of bypass time, as well as technique, route, and size of cannulation, are recorded. Open conversion to sternotomy and conventional AVR or surgical repair of complications, such as aortic dissection or access vessel complications, should be included and details provided clearly. If a second TAVR is needed due to malpositioning or paravalvular leak, the valve-in-valve procedure is described in the details. The method and
success of hemostasis are also documented, including details regarding surgical repair, if needed.

### 4.4.5. Congenital and Structural Heart Catheterization

Few fields cover as much variety in every aspect of anatomy, history, presentation, physical exam, physiology, diagnostic and interventional approaches, procedural technique, and follow-up events as CHD. Nonetheless, these procedures share sufficient commonalities with the other procedures described above to utilize the structured reporting construct of this HPS. Compared with adult cardiac catheterization, however, the clinical drivers of invasive assessment and intervention in this population emanate from first principles quite different from those applicable to adult acquired heart disease, and there is a paucity of quality outcomes analyses related to these procedures. Substantial work has been completed in developing pediatric nomenclatures, particularly the International Paediatric and Congenital Cardiac Code vocabulary \(^{40,41}\); these are to be used as the foundation of CHD structured catheterization procedure reports. Use of consistent terminology across the myriad of procedures performed to evaluate and treat CHD will in turn help advance understanding of the principles and practice of cardiac catheterization in this arena.

Although the specifics are much more varied than the other types of cardiovascular catheterization described above, the organization of the structured report and sections are more similar than different. The clinical question resulting in referral for catheterization is captured, along with a brief (prose) history, sufficiently broad to convey the context of the referral. This complements details of the history captured as data specific to the disease state and procedure being performed. Details of sedation, medication administration, anesthesia, and vascular support are captured in the corresponding sections of the structured procedure report. Short- and long-term clinical plans as modified by the outcome of the procedure are included in the impressions and recommendations sections.

Compared with adult cardiovascular disease, there are a greater number of modules (and much more overlap of those modules) in the congenital space. The diagnostic procedures include standard right and left heart cardiac catheterization as well as angiography of other vascular structures (Table 2). On the summary page, pertinent summary findings are to be listed, whereas a more complete tabular listing in the report body (details) section reflects the combination of anatomy, findings, and technical approach. This includes documentation of the conditions under which hemodynamics are obtained (with the recording of hemodynamics, such as the pressures and oximetry from cardiac chambers and vascular passages), together with unique aspects of hemodynamics.

For reporting congenital intervention, a series of templates is needed, given that intervention is used to open stenoses, close defects, and variations thereof (Table 3). Specific documentation regarding devices used, the anatomic and physiological targets of the intervention, technical success, and physiological measurements (pre and post) is included. In addition, specific and customizable diagrams that reflect unique physiologies, anatomic variants, structural abnormalities, and the interventions thereof are crucial to the graphics/images section of the report.

The principles described above (and throughout this HPS) similarly apply to reporting on structural heart disease and other catheterization procedures. These procedures include (but are not limited to) percutaneous valve implantation (in addition to TAVR), balloon valvuloplasty, percutaneous repair of mitral valve regurgitation, atrial appendage occlusion, and alcohol ablation of the septum in hypertrophic obstructive cardiomyopathy. We believe the examples described above and modeled in the prototypes (Tables 2 and 3) provide a template sufficient to create structured reports consistent with this HPS and have, therefore, not further represented these procedures in the report prototype tables.

### 4.4.6. Combination Procedures

The performance of multiple procedures in a single case setting occurs frequently in the catheterization laboratory. From a structured reporting perspective, the modular approach to organizing the collection and reporting of data in segments corresponding to the procedures performed allows for straightforward construction of a final, single, organized, and cogent procedure report. This “stacking” of report modules should logically follow the temporal sequence of the events that occurred in the catheterization visit. Note that this is not to facilitate “drive-by” procedures; just being in the lab for one procedure is not an indication for a second. Instead, this modular approach is to facilitate the complete reporting of all that transpired during a catheterization visit. Indeed, indications for all procedures performed need to be present in the final procedure report. Complex procedures also raise issues including radiation exposure and radiographic contrast media volume that must be carefully managed by the physician/operator(s).

One comprehensive report should be generated for the entire case so as to avoid confusion that could arise if multiple individual procedure reports are generated from a single patient visit to the catheterization suite. Reporting of these procedures must follow the standards set for the individual procedures being performed as described in the previous sections. The front page should clearly reflect the performance of each separate procedure within the total case. Demographics, history, and indications that support each procedure are required. Impressions and recommendations should reflect the entire set of procedures performed.

### 4.5. Structured Report Style Guide

The capture of structured data via structured reporting processes serves little utility if that same data cannot be presented in a format easily understood by human readers. Optimally, structured data are coupled with standardized templates to produce structured reports that require the least amount of cognitive processing to comprehend and assimilate. To accomplish this goal, this HPS calls for a certain degree of cross-vendor conformity with respect to the appearance and organization of catheterization procedure reports. Within this general framework, specifics of formatting (eg, conventions for indentation, alignment and justification, even font size) further reduce the cognitive burden, particularly when reading reports created by differing software solutions. To this end, a style guide has been created that articulates formatting recommendations for
the final structured procedure report. See the separate Cath Report Style Guide attachment.

The style guide builds on the content recommendations of the previous sections to detail the specifications for presentation of that content. The style recommendations focus on the consistency needed to improve the readability and usability of the (printed) physician-authored, final structured procedure report. A degree of consistency and reproducibility reduces the effort required to find specific pieces of information. A specific emphasis is the presentation of data in a tabular (table-based) formatted layout. This includes right justification to align labels and left justification to align data where feasible. For example, the layout of the pressure readings of a right heart catheterization might appear in text as the following:

Right Heart Catheterization

RA: a=6 v=4 mean=3 (If a wave is absent in atrial fibrillation, suggest N/A or −)  
RV: 30/7, EDP 11  
PA: 30/13, mean=18  
PCW: a=14 v=12 mean=10  
ΔAVO₂: 4.3 vol%  
CO: 4.4 L/min  
CI: 2.5 L/min/m²

The overall construct is to present information in a label: finding format. Inconsistent with structured reporting is presenting data as prose, whether the prose is created via dictation or a computerized conversion of data into a phrase. The sentence “The results of the right heart catheterization are as follows: RA a=6, v=4, and mean=3; RV 30/7, EDP 11; PA 30/13, mean=18; and PCW a=14, v=12, mean=10, AV O₂ difference of 4.3 volume percent, cardiac output of 4.4 L/min, and cardiac index of 2.5 L/min per m²” includes all the data; however, none of the prose elements (including the words added to create the sentence and the structure of the sentence itself) add anything to the meaning of the data. In fact, the prose substantially reduces the efficiency of comprehending and retaining the data as information.

As noted previously, report layout is purposefully modular. Certain sections are universal regardless of the procedure being performed. For example, a brief (prose) history, a tabular listing of the procedures performed, and the impressions and plans (prose) section appearing on the front page summary are universal to all procedures, as is the medications log in the report body. Depending on the actual procedures performed, the other sections of the report—history and physical data relevant to the procedure and the underlying disease state, procedural details, findings, interpretation, and recommendations—follow in the same general order regardless of the procedure. What varies is the content within each modular section, with the content specific to the procedure actually performed. Institutional preference for the use of a vendor-based or a “home-grown” standardized reporting system should be viewed in the context of the requirements of this HPS and compatibility with national registries and other reporting mechanisms. Finally, the choice of design and layout should also consider the distribution and forwarding of the report to the patient, referring physician, and primary care physician as an expected standard practice.

4.6. Data Export

A key objective of the capture of structured data is the interchange of the same data among information systems. To convert structured data into a printed format suitable for interpretation, the typical solution is to use a report writer application that converts the data stored in a database into a formatted layout that is pleasing to the human eye and understandable to the human mind. Similarly, to accomplish interoperability among information systems, the data in a database must be first converted into a file format suitable for data transfer, with labeling and organization of the data content following a specific set of rules so that the receiving system can interpret the file and convert the content back into consumable data.

The general specification endorsed by this HPS for this purpose is the HL7 Consolidated Clinical Document Architecture (C-CDA) standard, which is the standard for the electronic transfer of clinical information per the standards and certification for Stage 2 Meaningful Use of EHR. This specification has been further developed into a Cath Report Content (CRC) profile by the organization IHE and successfully balloted by HL7, inclusive of the specifications and discrete data elements for the CDA-format report for a PCI procedure. Although a detailed discussion of the specifics of the C-CDA standard and the supporting IHE CRC profile is well beyond the scope of this HPS, a requirement of conformance with this HPS is the ability of the system to export and import C-CDA documents specific to the cardiovascular catheterization procedures covered herein. Finally, it is anticipated that as the C-CDA becomes the electronic standard for the interoperable exchange of information, this format will become the standard for the transmission of data to registries such as the ACC NCDR CathPCI registry.

4.7. Paradigm Expansion

This ACC/AHA/SCAI HPS summarizes the rationale, principles, processes, and components of structured reporting in cardiovascular catheterization laboratories. The resulting structured procedure reports will be clear, concise, and practical. Compared with dictated reports, they will be readily interoperable among clinical information systems. We believe this basic paradigm to be easily extensible to other areas of cardiology, such as electrophysiology, and ultimately scalable to all procedure types, particularly those performed under semisterile conditions without routine general anesthesia. Of note, the workflows and data flows of the operating room environment are substantially different from the “laboratories” where cardiovascular catheterization and other semisterile procedures are typically performed, and thus the framework presented here will likely have less applicability to open surgical procedures.

As medicine moves into the era of EHRs, standardized structured reporting will ensure completeness of the capture of the data elements representing the key components of these procedures and operations.

5. Adoption and Implementation

Universal adoption of structured reporting processes for invasive cardiovascular catheterization requires both acknowledgement of benefits and acceptance of responsibilities by key groups. In order to stimulate the implementation of structured reporting, it is critical to articulate these aspects as they directly
affect physician operators, catheterization laboratory management and personnel, and the software vendor community.

For physician operators, the key benefit is that structured reporting is inherently more thorough, complete, and accurate than other approaches, particularly dictation. Both the quality and quantity of the information are enhanced, reducing potential compliance, regulatory, and legal liabilities. A complete set of data is captured that conveys the information needed to optimize care of the patient. Nonetheless, 3 concerns are typically expressed by physicians transitioning from dictation to structured reporting: 1) the time required to directly input data into a computer compared with dictation; 2) the additional learning and cognitive effort required to use computerized solutions; and 3) the difficulty of capturing complexity as data. Although dictation is admittedly time efficient, the actual amount of time required to enter data into a well-engineered, high-usability system can be approximately the same or less than that required to dictate, review, correct, and sign a dictated report. Furthermore, creation of a final procedure report within minutes of completing the procedure eliminates the need for a preliminary handwritten or hand-typed report (and the time required thereof). The communication of standardized findings and technical details to referring clinicians via the EHR will be faster, more efficient, and more accurate. The systematic collection of standardized procedural data elements provides high-quality data for process and performance improvement, comparative effectiveness and other types of clinical research, and drug and device surveillance. It can also be used to populate state and national registries, inform health services research, and generate the foundation for feedback-based lifelong learning and maintenance of certification opportunities.

For catheterization laboratory staff, a period of transition and adaptation to new structured reporting processes will be followed by greater coordination of activities with less redundancy and repetition, thus allowing the staff to focus more attention and energy on the delivery of care. Given the degree of coordination required to optimize a structured reporting environment, education and training of staff is critical in accomplishing a smooth transition; therefore, a budget for training programs must be anticipated prospectively. Unquestionably, structured data collection offers the potential to achieve operational efficiencies and inventory management gains as well as optimized catheterization laboratory workflows. By using well-defined data standards, operational insights can be shared among institutions and across systems to develop and refine best practice workflows. Additionally, ongoing monitoring of performance measure data will foster an environment based on individual accountability and identify areas for potential improvement.

The success of structured reporting is highly dependent upon the software vendor community. While the most obvious and visible product of a structured reporting approach is the structured report itself, this is only 1 aspect of the totality of requirements and responsibilities of vendors (Table 4). The structured reporting system must recognize the sources of information, data to be captured, the actors (personnel handling the data), and data output at each step of the process of a catheterization procedure, starting with the scheduling of the patient through the generation of the final procedure report (see the separate Cath Report Sample attachment). In other words, the focus should be on the tasks and the way the tasks are accomplished, with the technology solutions designed to support the task flow. In this model, the input devices (eg, tablets and workstations) are optimized to the data management requirements of each step. The data model of the database must be both robust and flexible, not only to capture data associated with a specific episode of care, but also to span multiple episodes. The human interfaces used to capture the data must be maximally efficient and effective, built using principles of human factors and ergonomics. A key metric of success—perhaps singularly the most powerful criterion of all—is the capability to generate the final procedure report within a few minutes of the completion of the catheterization procedure. Anything less will mean that the potential of structured reporting has not been realized. Furthermore, it is anticipated that the vendor community will have a key role in teaching best-practice structured reporting processes to healthcare enterprises.

As the expertise that must be brought together to create an integrated structured reporting environment is spread across multiple disciplines, partnership between the professional societies and the vendor community is required to identify best practices, specify requirements, evaluate solutions, iteratively improve systems, and promulgate structured reporting processes. To this end, the ACC/AHA/SCAI anticipates that the development and deployment of structured reporting in the catheterization suite will be an ongoing process for some period of time. The expectation is that the physiological monitoring, procedure reporting, and EHR vendor communities will respond quickly to create linkages between the wealth of information entered into the physiological recorder and

**Table 4. Vendor Responsibilities**

- **Usability:** interfaces designed and built for maximum efficiency (human factors design)
- **Input devices:** specific to use case (eg, workstations, tablets, interfaces with hemodynamic and administrative systems)
- **Input handling:** use of controlled vocabulary with specific permissible values, range checking, consistency checking, other types of data validation on input
- **Database:** based on a patient-centric (not procedure-centric) data model, use of a controlled vocabulary
- **Outputs:** structured report per specifications of this HPS including health information exchanges for a full report and reporting to registries such as the NCDR for subset data
- **Interoperability:** adherence to the IHE CRC profile, which specifies catheterization report content; the IHE CATH profile, which specifies the basic patient data flow of catheterization procedures; and ACC/AHA Task Force on Data Standards key data elements for cardiac imaging documents
- **Partnership with professional societies in developing the structured reporting environment**
- **Dissemination of best practices in structured reporting to the user community**
- **Report exchange:** seamless movement of procedure reports between procedure reporting systems and EHR systems
- **Graphics:** software solution for the graphical depiction of anatomic findings and treatment results

ACC indicates American College of Cardiology; AHA, American Heart Association; CATH, cardiac catheterization workflow; CRC, catheterization report content; EHR, electronic health record; HPS, Health Policy Statement; IHE, Integrating the Healthcare Enterprise; and NCDR, National Cardiovascular Data Registry.
6. Extending the Structured Reporting Use Case

Professional societies active in the cardiovascular field have critical roles in defining and establishing the guidelines and performance metrics for cardiovascular procedures. Comprising voluntary representatives, societies have the responsibility for determining standards, norms, and expectations of professionalism of their members. No one is better positioned to understand the issues involved. As developers and shapers of clinical guidelines, performance measures, AUC, and educational and training programs that produce the specialists trained in these procedures, professional societies must lead the efforts to establish standards in reporting.

As described in this document, I critically important task in this effort is establishing a controlled vocabulary or terminology of relevant data elements for catheterization procedures. The individual terms selected for inclusion in this controlled vocabulary must be clinically appropriate and relevant to the patient and the procedure, and have precise and mutually agreed upon definitions so that the elements have unambiguous shared meanings (ie, semantic interoperability). Closely aligned with data element specification is determination of the data structures that combine individual elements into meaningful statements. It is the combination of a controlled vocabulary and a data structure that provides semantic interoperability. Although these concepts may seem obtuse to clinicians, they are crucially important for ensuring that data can be transmitted, received, and used as real information.

In order to obtain compatibility with EHRs and operate across computer networks, the standardized data elements and structures must meet technical language standards for data interchange. The primary technical standard for procedure report data structures is the HL7 CDA, with terminology encoded using recognized vocabulary standards such as the SNOMED/CT, the ICD-9 and ICD-10, the Logical Observation Identifiers Names and Codes for laboratory values, and RxNorm for drugs and pharmacy systems. However, these lexicons are relatively incomplete for representing the depth and breadth of cardiovascular procedure terminology, so stewardship of the controlled vocabulary of standardized data elements is required of the cardiovascular professional societies. As the primary performers, interpreters, and users of the procedures, these societies must maintain close supervision of the specialized vocabulary. Other data element terminology coding systems will have to be mapped and cross-referenced with the professional society system in order to ensure appropriate correspondences and eliminate confusion. This necessarily entails collaboration to help establish and maintain the formal technical features required of a controlled vocabulary compatible with EHRs and operating on multiple computer networks in the healthcare environment. An example of this is the International Society for Pediatric and Congenital Heart Disease. Founded in 2000, the International Society for Pediatric and Congenital Heart Disease is a multinational and multisocietal group composed of cardiologists, cardiac surgeons, cardiac pathologists, and morphologists. Since the group was founded, it has been tasked with developing a common and harmonized hierarchical coding structure of terms and definitions identified as the International Pediatric and Congenital Cardiac Code (IPCCC). The IPCC has been endorsed or adopted by a number of pediatric specialty societies in Europe and the United States. The challenge and also the opportunity are that constant interaction among all the groups, with constant review and periodic revision, will be necessary.

In the past, catheterization laboratory accreditation standards did not mandate structured reporting. However, this is changing. In the recently published 2012 Expert Consensus Document on Cardiac Catheterization Laboratory Standards, the recommendation is made that a structured report using standardized data should be finalized in a timely fashion following procedure completion. The ACC- and SCAI-endorsed Accreditation for Cardiovascular Excellence program (www.cvexcel.org) specifies the generation of structured reports as a criterion for accreditation, similar to criteria established by the respective Intersocietal Commissions in echocardiography, nuclear cardiology, and cardiac magnetic resonance imaging (www.intersocietal.org). In short, structured reporting must be considered 1 component of the overall quality improvement imperative for cardiovascular care.

ACC President and Staff

John Gordon Harold, MD, MACC, President
Shalom Jacobovitz, Chief Executive Officer
William J. Oetgen, MD, MBA, FACC, Executive Vice President, Science, Education, and Quality
Charlene L. May, Senior Director, Science and Clinical Policy
Dawn R. Phoubandith, MSW, Director, ACC Clinical Documents
Tanja Kharlamova, Associate Director, Clinical Policy and Documents
Tiffany M. Jones, MA, Specialist, Clinical Policy and Documents
AnneMarie Boeve, Specialist, Clinical Policy and Documents
Amelia Scholtz, PhD, Publications Manager, Clinical Policy and Pathways
Acknowledgment
We wish to acknowledge Frances L. Kosik, RN, MSN, MPH, for her foundational contributions to the development of this health policy statement.

References


KEY WORDS: AHA Scientific Statements ◼ best practice model ◼ cardiac catheterization ◼ cardiac catheterization laboratory workflow ◼ clinical data interchange ◼ clinical document architecture ◼ electronic health records ◼ percutaneous coronary interventions ◼ structured reporting
## Appendix 1. Author Relationships With Industry and Other Entities (Relevant)—ACC/AHA/SCAI 2014 Health Policy Statement on Structured Reporting for the Cardiac Catheterization Laboratory

<table>
<thead>
<tr>
<th>Committee Member</th>
<th>Employment</th>
<th>Consultant</th>
<th>Speaker’s Bureau</th>
<th>Ownership/Partnership/Principal</th>
<th>Personal Research</th>
<th>Institutional, Organizational, or Other Financial Benefit</th>
<th>Expert Witness</th>
</tr>
</thead>
<tbody>
<tr>
<td>Timothy Sanborn (Chair)</td>
<td>North Shore University Health System—Professor of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>James Tcheng (Vice Chair)</td>
<td>Duke University Medical Center—Professor of Medicine</td>
<td>• Cardiovascular Systems</td>
<td>None</td>
<td>None</td>
<td>• National Institutes of Health*</td>
<td>• Duke University Medical Center*</td>
<td>None</td>
</tr>
<tr>
<td>H. Vernon Anderson</td>
<td>University of Texas Cardiology Division—Professor of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Charlie Chambers</td>
<td>Penn State Milton S. Hershey Medical Center—Professor of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Sharon Cheatham</td>
<td>Nationwide Children’s Hospital—Interventional Cardiology Nurse Practitioner</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Matthew V. DeCaro</td>
<td>Jefferson University Hospitals—Director, Coronary Care Unit; Assistant Professor</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Jeremy Durack</td>
<td>Memorial Sloan-Kettering Cancer Center—Interventional Radiologist</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Allen Everett</td>
<td>Johns Hopkins Hospital—Associate Professor Pediatric Cardiology</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>John Gordon</td>
<td>San Diego Cardiac Center Medical Corporation—Cardiologist</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>William Hammond</td>
<td>Duke Center for Health Informatics—Director</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Ziyad Hijazi</td>
<td>James A. Hunter, MD, University, Rush Center for Congenital &amp; Structural Heart Disease—Chair Professor of Pediatrics &amp; Internal Medicine Director</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Vikram S. Kashyap</td>
<td>Case Western Reserve University, Harrington Heart and Vascular Institute—Professor of Surgery and Chief, Division of Vascular Surgery and Endovascular Therapy; University Hospitals Case Medical Center—Co-Director</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Merrill Knudtson</td>
<td>University of Calgary—Professor of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Michael Landzberg</td>
<td>BACH Pulmonary Hypertension Service, Departments of Pediatrics, Medicine, Surgery—Medical Director, Boston Adult Congenital Heart</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>
### Appendix 1. Continued

<table>
<thead>
<tr>
<th>Committee Member</th>
<th>Employment</th>
<th>Consultant</th>
<th>Speaker’s Bureau</th>
<th>Ownership/Partnership/Principal</th>
<th>Personal Research</th>
<th>Institutional, Organizational, or Other Financial Benefit</th>
<th>Expert Witness</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marco A. Martinez-Rios</td>
<td>Instituto Nacional de Cardiología de Mexico—Director General</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Lisa Riggs</td>
<td>St. Luke’s Hospital—Director of CV Quality</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>• 2012, Defendant, post-procedural bleeding</td>
</tr>
<tr>
<td>Kui Hian Sim</td>
<td>Sarawak General Hospital, Malaysia—Visiting Senior Consultant Cardiologist</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>David Slotwiner</td>
<td>Long Island Jewish Medical Center—Associate Director, Electrophysiology Laboratory</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Harry Solomon</td>
<td>GE Healthcare—Interoperability Architect</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>General Electric Healthcare</td>
<td>None</td>
</tr>
<tr>
<td>Wilson Y. Szeto</td>
<td>Hospital of the University of Pennsylvania Division of Cardiothoracic Surgery—Surgical Director, Transcatheter Cardio-Aortic Therapies—Associate Director, Thoracic Aortic Surgery Program; Associate Chief of Cardiovascular Surgery please</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Bonnie Weiner</td>
<td>St. Vincent Hospital Worcester Medical Center—Training Director</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>William Weintraub</td>
<td>Christiana Care Health System—Section Chief, Cardiology</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>• 2012, Defendant, celebrex litigation</td>
<td>• 2011, Defendant, oral contraceptive litigation</td>
</tr>
<tr>
<td>John Windle</td>
<td>University of Nebraska Medical Center Cardiology Section—Professor and Chief, Internal Medicine, Division of Cardiology</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$10,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted.

According to the ACC, a person has a relevant relationship if: a) The relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document; or b) The company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the document, or makes a competing drug or device addressed in the document; or c) The person or a member of the person’s household, has a reasonable potential for financial, professional, or other personal gain or loss as a result of the issues/content addressed in the document.

*Significant relationship.
†No financial benefit.

ACC indicates American College of Cardiology; AHA, American Heart Association; and SCAI, Society for Cardiovascular Angiography and Interventions.
## Appendix 2. Peer Reviewer Relationships With Industry and Other Entities (Relevant)—ACC/AHA/SCAI 2014 Health Policy Statement on Structured Reporting for the Cardiac Catheterization Laboratory

<table>
<thead>
<tr>
<th>Peer Reviewer</th>
<th>Representation</th>
<th>Employment</th>
<th>Consultant</th>
<th>Speaker’s Bureau</th>
<th>Ownership/Partnership/Principal</th>
<th>Personal Research</th>
<th>Institutional, Organizational, or Other Financial Benefit</th>
<th>Expert Witness</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deepak L. Bhatt</td>
<td>Official Reviewer—CQC Lead Reviewer</td>
<td>Brigham and Women’s Hospital Heart and Vascular Center; Harvard Medical School—Executive Director of Interventional Cardiovascular Programs; Professor of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Medtronic†</td>
<td>None</td>
</tr>
<tr>
<td>Gregory Dehmer</td>
<td>Official Reviewer—ACC BOT</td>
<td>Texas A&amp;M, College of Medicine, Scott &amp; White Clinic Cardiology Division—Professor of Medicine; Director of Cardiology</td>
<td>Clinical Advisory Group, Maryland</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Jacqueline Kreutzer</td>
<td>Official Reviewer—AHA</td>
<td>Children’s Hospital of Pittsburgh—Director, Cardiac Catheterization Laboratory</td>
<td>Medtronic</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Sunil Rao</td>
<td>Official Reviewer—SCAI</td>
<td>Duke Cardiology—Associate Professor of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Rose Shaffer</td>
<td>Official Reviewer—AHA</td>
<td>Thomas Jefferson University Hospital—Cardiology Nurse Practitioner</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Barry Uretsky</td>
<td>Official Reviewer—SCAI</td>
<td>University of Arkansas Medical Sciences—Clinical Professor of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Robert Vincent</td>
<td>Official Reviewer—IASC</td>
<td>Children’s Healthcare of Atlanta—Co-Medical Director, Heart Transplant Program; Director, Cardiac Catheterization Lab; Pediatric Cardiologist</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>• AGA*</td>
<td>None</td>
</tr>
<tr>
<td>Tom Dolan</td>
<td>Organizational Reviewer—DICOM</td>
<td>Philips Healthcare—Director Interoperability and Standards</td>
<td>Integrating the Healthcare Enterprise*</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Bob Dolin</td>
<td>Organizational Reviewer—HL7</td>
<td>Lantana Consulting Group, Health Level Seven—President and Chief Medical Officer</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

(Continued)
### Appendix 2. Continued

<table>
<thead>
<tr>
<th>Peer Reviewer</th>
<th>Representation</th>
<th>Employment</th>
<th>Consultant</th>
<th>Speaker’s Bureau</th>
<th>Ownership/Partnership/Principal</th>
<th>Personal Research</th>
<th>Institutional, Organizational, or Other Financial Benefit</th>
<th>Expert Witness</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jorge Gaspar-Hernandez</td>
<td>Organizational Reviewer—IASC</td>
<td>Instituto Nacional De Cardiologia—</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>Boris Nikolic</td>
<td>Organizational Reviewer—SIR</td>
<td>Albert Einstein Medical Center—Interventional Radiologist</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>Blair O’Neill</td>
<td>Organizational Reviewer—CCS</td>
<td>Mazankowski Alberta Heart Institute—Head, Division of Cardiology</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>Kristine J. Peterson</td>
<td>Organizational Reviewer—AACN</td>
<td>Aspirus Wausau Hospital—Cardiac Clinical Nurse Specialist</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>Teri M. Sippel Schmidt</td>
<td>Organizational Reviewer—Integrating the Healthcare Enterprise</td>
<td>Radiological Society of North America—Technical Project Manager, IHE Cardiology</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>Sunarya Soerianata</td>
<td>Organizational Reviewer—APSC</td>
<td>Indonesian Heart Association—President</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>• Defendant, brachial artery pseudoaneurysm, 2013</td>
</tr>
<tr>
<td>Ravi Veeraswamy</td>
<td>Organizational Reviewer—SVS</td>
<td>Emory University School of Medicine—Associate Professor of Surgery</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>Gary Webb</td>
<td>Organizational Reviewer—ISACHD</td>
<td>Cincinnati Children’s Hospital Medical Center—Director, Cincinnati Adolescent and Adult Congenital Heart Center</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>Mathew R. Williams</td>
<td>Organizational Reviewer—STS</td>
<td>New York Presbyterian Hospital-Columbia—Co-Director, Heart Center</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>• Edwards Lifesciences • Medtronic</td>
</tr>
<tr>
<td>Anita Arnold</td>
<td>Content Reviewer—Advocacy Steering Committee</td>
<td>USF Department of Cardiology Tampa Florida—Assistant Professor of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>Herbert Aronow</td>
<td>Content Reviewer—PVD Committee</td>
<td>St. Joseph Mercy Ann Arbor—Cardiovascular Disease Specialist</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>Eric Bates</td>
<td>Content Reviewer—PCI GL</td>
<td>University of Michigan Hospitals and Health Centers—Professor of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>Lisa Bergersen</td>
<td>Content Reviewer—ACPC</td>
<td>Children’s Hospital Boston—Assistant Professor of Pediatrics</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>Peer Reviewer</td>
<td>Representation</td>
<td>Employment</td>
<td>Consultant</td>
<td>Speaker’s Bureau</td>
<td>Ownership/Partnership/Principal</td>
<td>Personal Research</td>
<td>Institutional, Organizational, or Other Financial Benefit</td>
<td>Expert Witness</td>
</tr>
<tr>
<td>---------------</td>
<td>----------------</td>
<td>------------</td>
<td>------------</td>
<td>------------------</td>
<td>-------------------------------</td>
<td>-------------------</td>
<td>------------------------------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Thomas Bashore</td>
<td>Content Reviewer—Cath Lab Standards ECD</td>
<td>Duke University Medical Center—Senior Vice Chief of Cardiology</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>James Blankenship</td>
<td>Content Reviewer—PCI GL</td>
<td>Geisinger Medical Center—Director, Cardiac Catheterization Lab</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Joaquin Cigarroa</td>
<td>Content Reviewer—ISC</td>
<td>Oregon Health &amp; Science University—Associate Professor of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Defendant, Coronary artery disease review, 2011</td>
</tr>
<tr>
<td>Stephen Ellis</td>
<td>Content Reviewer—Informatics Committee</td>
<td>Cleveland Clinic Foundation—Director, Sones Cardiac Catheterization Lab</td>
<td>• Abbott Vascular</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Phillip Greenland</td>
<td>Content Reviewer—Council on CV Care in Older Adults</td>
<td>Northwestern University Feinberg School of Medicine—Professor and Chair, Department of Preventive Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Glenn Levine</td>
<td>Content Reviewer—PCI GL</td>
<td>Baylor College of Medicine; Michael E. DeBakey Medical Center—Professor of Medicine; Director, Cardiac Care Unit</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Marian Limacher</td>
<td>Content Reviewer—Provider Radiation Safety ECD</td>
<td>University of Florida Division of Cardiovascular Medicine—Suncoast Endowed Professor of Cardiovascular Medicine Research</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>NIH†</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Howard C. Lewin</td>
<td>Content Reviewer—Imaging Council</td>
<td>Positron Imaging Partners in Los Angeles—Medical Director</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Plaintiff, interpretation of perfusion scan, 2012</td>
</tr>
<tr>
<td>Ehtisham Mahmud</td>
<td>Content Reviewer—ISC</td>
<td>University of California San Diego, School of Medicine—Chief of Cardiovascular Medicine</td>
<td>• Medtronic</td>
<td>• Medtronic</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Sandra Oliver-McNeil</td>
<td>Content Reviewer—Cardiovascular Care Team</td>
<td>William Beaumont Hospital; Wayne State University—Nurse Practitioner; Assistant Professor</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Debabrata Mukherjee</td>
<td>Content Reviewer—ISC</td>
<td>Texas Tech University Health Science Center—Chief, Cardiovascular Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>
### Appendix 2. Continued

<table>
<thead>
<tr>
<th>Peer Reviewer</th>
<th>Representation</th>
<th>Employment</th>
<th>Consultant</th>
<th>Speaker’s Bureau</th>
<th>Ownership/Partnership/Principal</th>
<th>Personal Research</th>
<th>Institutional, Organizational, or Other Financial Benefit</th>
<th>Expert Witness</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manesh Patel</td>
<td>Content</td>
<td>Duke University</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>Appropriate Use Criteria; AUC for Diagnostic Catheterization; AUC for Coronary Revascularization</td>
<td>Medical Center—Director of Interventional Cardiology and Cardiac Catheterization Labs</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rajan Patel</td>
<td>Content</td>
<td>Ochsner Medical Center—Interventional Cardiologist</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>Imaging Council</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Marwan Refaat</td>
<td>Content</td>
<td>American University of Beirut—Assistant Professor of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>EP Committee</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vinod Thourani</td>
<td>Content</td>
<td>Emory University Division of Cardiothoracic Surgery—Associate Professor of Surgery</td>
<td>None</td>
<td>Edwards Lifesciences</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>Reviewer—Surgeon Scientific Council</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Henry H. Ting</td>
<td>Content</td>
<td>Mayo Clinic—Professor of Medicine; Director, Mayo Clinic Quality Academy</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>Reviewer—Task Force on Performance Measures</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Robert Touchon</td>
<td>Content</td>
<td>Huntington Internal Medicine Group—Member, Cardiology Staff</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>Prevention Committee</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Robert Vincent</td>
<td>Content</td>
<td>Children’s Healthcare of Atlanta—Co-Medical Director, Heart Transplant Program; Director, Cardiac Catheterization Lab; Pediatric Cardiologist</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>Reviewer—ACPC (and Official BOG)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thad Waites</td>
<td>Content</td>
<td>Mississippi State Board of Health; Hattiesburg Clinic; Forrest General Hospital—Cardiologist; Director of Catheterization Lab</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>Reviewer—Advocacy Steering Committee</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This table represents the relationships of reviewers with industry and other entities that were disclosed at the time of peer review and determined to be relevant to this document. It does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$10,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Names are listed in alphabetical order within each category of review. Please refer to http://www.cardiosource.org/Science-And-Quality/Practice-Guidelines-and-Quality-Standards/Relationships-With-Industry-Policy.aspx for definitions of disclosure categories or additional information about the ACC Disclosure Policy for writing committees.

According to the ACC, a person has a relevant relationship IF: a) The relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document; or b) The company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the document, or makes a competing drug or device addressed in the document; or c) The person or a member of the person’s household, has a reasonable potential for financial, professional, or other personal gain or loss as a result of the issues/content addressed in the document.

*No financial benefit.
†Significant relationship.

ACC indicates American College of Cardiology; AACN, American Association for Cardiac-Care Nurses; ACPC, Adult Congenital and Pediatric Cardiology; AHA, American Heart Association; APSC, Asian Pacific Society of Cardiology; BOG, Board of Governors; BOT, Board of Trustees; CCS, Canadian Cardiology Society; CQC, Clinical Quality Committee; CV, Cardiovascular; DICOM, Digital Imaging and Communications in Medicine; ECD, expert consensus document; EP, electrophysiology; HL7, Health Level Seven; IASC, Inter-American Society of Cardiology; ISACHD, International Society of Adult Congenital Heart Disease; ISC, Interventional Scientific Council; PCI GL, percutaneous coronary intervention guideline; PVD, peripheral vascular disease; SCAI, Society for Cardiovascular Angiography and Interventions; SIR, Society of Interventional Radiology; STS, Society of Thoracic Surgeons; and SVS, Society for Vascular Surgery.
### Appendix 3. Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AACN</td>
<td>American Association for Cardiac-Care Nurses</td>
</tr>
<tr>
<td>ACC</td>
<td>American College of Cardiology Foundation</td>
</tr>
<tr>
<td>AHA</td>
<td>American Heart Association</td>
</tr>
<tr>
<td>APP</td>
<td>Advanced Practice Practitioners</td>
</tr>
<tr>
<td>APSG</td>
<td>Asian Pacific Society of Cardiology</td>
</tr>
<tr>
<td>AUC</td>
<td>appropriate use criteria</td>
</tr>
<tr>
<td>AVR</td>
<td>aortic valve replacement</td>
</tr>
<tr>
<td>CART</td>
<td>Clinical Assessment, Reporting, and Tracking System for Cath Labs</td>
</tr>
<tr>
<td>C-CDA</td>
<td>Consolidated Clinical Document Architecture</td>
</tr>
<tr>
<td>CCS</td>
<td>Canadian Cardiovascular Society</td>
</tr>
<tr>
<td>CDA</td>
<td>Clinical Document Architecture</td>
</tr>
<tr>
<td>CDISC</td>
<td>Clinical Data Interchange Standards Consortium</td>
</tr>
<tr>
<td>CHD</td>
<td>congenital heart disease</td>
</tr>
<tr>
<td>CQC</td>
<td>Clinical Quality Committee</td>
</tr>
<tr>
<td>CRC</td>
<td>Cath Report Content</td>
</tr>
<tr>
<td>DICOM</td>
<td>Digital Imaging and Communications in Medicine</td>
</tr>
<tr>
<td>EHR</td>
<td>electronic health record</td>
</tr>
<tr>
<td>HITECH</td>
<td>Health Information Technology for Economic and Clinical Health</td>
</tr>
<tr>
<td>HL7</td>
<td>Health Level Seven, Incorporated</td>
</tr>
<tr>
<td>HPS</td>
<td>health policy statement</td>
</tr>
<tr>
<td>IASC</td>
<td>InterAmerican Society of Cardiology</td>
</tr>
<tr>
<td>ICD</td>
<td>International Classification of Diseases</td>
</tr>
<tr>
<td>IHE</td>
<td>Integrating the Healthcare Enterprise</td>
</tr>
<tr>
<td>IPCCC</td>
<td>International Pediatric and Congenital Cardiac Code</td>
</tr>
<tr>
<td>ISACHD</td>
<td>International Society of Adult Congenital Heart Disease</td>
</tr>
<tr>
<td>MHT</td>
<td>multidisciplinary heart team</td>
</tr>
<tr>
<td>NCOR</td>
<td>National Cardiovascular Data Registry</td>
</tr>
<tr>
<td>PCI</td>
<td>percutaneous coronary intervention</td>
</tr>
<tr>
<td>RWI</td>
<td>relationships with industry and other entities</td>
</tr>
<tr>
<td>SCAI</td>
<td>Society for Cardiovascular Angiography and Interventions</td>
</tr>
<tr>
<td>SIR</td>
<td>Society of Interventional Radiology</td>
</tr>
<tr>
<td>SNOMED CT</td>
<td>Systemized Nomenclature of Medicine – Clinical Terms</td>
</tr>
<tr>
<td>STS</td>
<td>Society of Thoracic Surgeons</td>
</tr>
<tr>
<td>SVS</td>
<td>Society for Vascular Surgery</td>
</tr>
<tr>
<td>TAVR</td>
<td>transcatheter aortic valve replacement</td>
</tr>
<tr>
<td>UMLS</td>
<td>Unified Medical Language System</td>
</tr>
<tr>
<td>XDS</td>
<td>Cross Enterprise Document Sharing</td>
</tr>
</tbody>
</table>
ACC/AHA/SCAI 2014 Health Policy Statement on Structured Reporting for the Cardiac Catheterization Laboratory: A Report of the American College of Cardiology Clinical Quality Committee


Circulation. 2014;129:2578-2609; originally published online March 28, 2014; doi: 10.1161/CIR.0000000000000043

Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2014 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/129/24/2578

Data Supplement (unedited) at:
http://circ.ahajournals.org/content/suppl/2014/03/24/CIR.0000000000000043.DC1
http://circ.ahajournals.org/content/suppl/2014/03/24/CIR.0000000000000043.DC2

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org/subscriptions/
Cardiac Catheterization Procedure Report Summary

Primary Indication
Chest pain (786.50)

History
A 57-year old man with hyperlipidemia, hypertension, and a positive family history who presents with typical chest discomfort with exertion relieved with rest. A stress echocardiogram was positive for a large area of ischemia involving the anterior and anterolateral distributions.

Procedures
Left heart cath + ventriculogram + coronary angiography (93458)
Percutaneous coronary intervention: prox LAD, prox-mid LCX (92928, 92929)
Intra-aortic balloon pump (33967)

Vascular Access
Location: right radial artery, right femoral artery
Sheath: 5Fr (right radial), 6Fr (right femoral)
Disposition (end of case): radial – TR band; femoral – hemostasis with Brand EE closure device

Catheters
Diagnostic: JL4, JR4, Amplatz 1, pigtail
Intervention: XB 3.5, Amplatz 2

Diagnostic Findings
Hemodynamics (mm Hg)
Aorta: 134/78, mean 92
LV: 134/4, EDP 18

Coronary arteries
Left dominant
Prox LAD: 90%
Prox-mid LCX: diffuse 80%
OM3: 60%
RCA: normal

Left ventricle
EF: 61%
MR: 1+ mild
Wall motion: mild anterior hypokinesis, moderate apical hypokinesis

Interventions
Prox LAD: Brand MM 3.0mm x 18mm (drug eluting) stent: 90% pre to 0% post
Prox-mid LCX: Brand NN 3.0mm x 28mm (bare metal) stent: diffuse 80% pre to 10% post

Adverse Events
Ventricular fibrillation
Medication Totals
- Diphenhydramine: 25 mg
- Heparin: 5000 units
- Hydromorphone: 1 mg
- Clopidogrel: 600 mg
- Midazolam: 1 mg
- Antacid: 30 ml

Contrast Total
- Iopamidol: 140 ml

Impressions
- 2 vessel coronary artery disease
- Successful PCI x2

Recommendations
- Risk factor modification
- Routine post-PCI care
- Refer for cardiac rehab
- Aspirin 81 mg lifelong
- P2Y12 inhibitor for at least 6 months
- Avoid elective surgery while receiving a P2Y12 inhibitor

Physician
- Richard Green, MD
- Pamela Blue, DO

Attending attestation: I was present for the entire procedure.
Cardiac Catheterization Laboratory
[Name of facility]
[Logo of facility]

Patient: Last name, first name
[middle initial /name]

MRN: xxxxxxxx  DOB: xx/xx/xxxx  Age: xx
Gender: M/F
Procedure Date: xx/xx/xxxx
Cine Number: xxxxx
Cath Attending: xxxxxxxx xxxxxxxxx
Referring Provider: xxxxxxxx xxxxxxxxx

Patient
Last name, first name  middle name / initial
Date of birth, age, gender
Race, ethnicity
Medical record number
Case accession number
Insurance

Healthcare Facility
The Heart Hospital
Adult Cardiac Catheterization Laboratory
2000 Applewood Lane
Eureka, Texas  75100
(555) 555-1111
FAX: (555) 5555-1234
Laboratory: Cath Lab 2

Operator
Richard Green, MD
Pamela Blue, DO (fellow)

Staff
Carrie Brown, RN
Samuel White, CVT
Samantha Rose, RN
Deborah Black, RN

Care Providers
Referred by: John Grey, MD
2000 Southfork Ranch Road
Dallas, TX  71234
(813) 555-1212
Primary Care Provider: Barney Redd, MD
1000 Cahuna Ranch Boulevard
Arlington, TX 72345
(714) 555-1212
Cardiologist: Ray Ivory, DO
3000 Workman Ranch Street
Irving, TX 73456
(615) 555-1212

Reason for request: evaluation of decompensated heart failure with chest pain.
Procedure requested: left heart cath
Date of request: January 2, 2013
Requested by: John Grey, MD
Encounter Category
Elective cath, possible PCI

History and Physical Data

Symptom Class – Angina
Onset: 12/?/?2007
Current CCS class: asymptomatic

Symptom Class – Heart Failure
Onset: 12/?/?2007
Current NYHA class: asymptomatic

Medical History
Diabetes mellitus, type II: on oral meds
Total cholesterol >200
LDL >100
Cigarette smoking: average of 2.5 packs per day x 25 year
Hypertension
Renal insufficiency: CKD stage 3
Cardiac transplant: 1/4/2009
Steroid use, chronic

Previous Procedures / Previous Events
12/18/2007 High Point Regional Hospital: acute MI
12/18/2007 High Point Regional Hospital: LHC, PCI - mid LAD
7/10/2008 Duke University Medical Center: LHC
9/21/2008 Duke University Medical Center: RHC, LHC
1/4/2009 Duke University Medical Center: cardiac transplant
1/11/2009 Duke University Medical Center: RHC, biopsy
2/11/2009 Duke University Medical Center: biopsy
5/15/2009 Duke University Medical Center: stress echo, anterior and anterolateral ischemia

Allergies and Sensitivities
Penicillin: rash (moderate)

Physical Examination
Lungs: clear
Heart: normal S1 and S2
Pulses:

<table>
<thead>
<tr>
<th></th>
<th>carotid</th>
<th>femoral</th>
<th>DP</th>
<th>PT</th>
</tr>
</thead>
<tbody>
<tr>
<td>left</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>right</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
</tbody>
</table>

Bruits:

<table>
<thead>
<tr>
<th></th>
<th>left</th>
<th>right</th>
</tr>
</thead>
<tbody>
<tr>
<td>left</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>right</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

Neurologic: alert & oriented x3

Laboratories
Hemoglobin 12.2 g/dL [13.7-17.3] 11/30/2011
Hematocrit  36 L/L  [0.39-0.49]  11/30/2011
Platelets  349 X10^9  [150-450]  11/30/2011
Sodium  138 mmol/L  [135-145]  11/30/2011
Potassium  4.5 mmol/L  [3.5-5.0]  11/30/2011
Urea nitrogen  33.0 mg/dL  [7-20]  11/30/2011
Creatinine  1.9 mg/dL  [0.6-1.3]  11/30/2011

**ICD Diagnoses** (*indicates primary indication)
*V42.1 Heart replaced by transplant
585.3 Chronic kidney disease, stage 3 (GFR 59-30)
401.1 Benign essential hypertension
426.4 Right bundle branch block (RBBB)
V58.65 Steroids, long term (current) use of
V58.66 Aspirin, long term (current use)

**AUC Indications**
Diagnostic cath: criterion 101 (post heart transplant patient)
Intervention: criterion 10 (UA/NSTEMI and intermediate risk features)

**PROCEDURE DETAILS**

**Procedures**
- Endomyocardial biopsy
- Right heart catheterization
- Fick cardiac output
- Aortic pressure measurement
- Left heart catheterization
- Coronary angiogram - left
- Coronary angiogram - right
- Drug-eluting stent – single vessel

**Logistics**
- Time arrived in lab: 11:40, from CVSSU
- Consent signed: yes
- Sedation consent: yes
- Timeout performed: yes
- Time departed from lab: 13:11, to CVSSU
- Final patient condition: stable

**Baseline Data**
- Height: 172.0 cm
- Weight: 73.7 kg
- BSA: 1.80 m2
- Initial blood pressure: 125/67 mmHg
- Initial pulse: 66 bpm
- eGFR: 77 mL/min

**Vascular Access**
- Right femoral vein: SheathCo 7Fr Slider sheath, Hemo 7Fr Intro 85cm (biopsy sheath)
  - Disposition: removed, hemostasis via manual compression
- Right femoral artery: SheathCo 5Fr Slider sheath
  - Disposition: removed, hemostasis via manual compression
**Hemodynamic Support**

Left femoral artery: Datascope 40 cc intra-aortic balloon pump, inserted at 11:45
Disposition: left in place
Diagnostic Findings

Right Heart Catheterization

Instruments: Bard 7Fr Pulmonary Wedge Pressure Catheter

Oximetry, Cardiac Output, and Calculated Data
Assessment conditions: rest
- Patient height: 172.0 cm, weight: 73.7 kg, body surface area: 1.80 m²
- Vital signs: HR: 92 bpm, BP: 131/104 mmHg
- Inspired O2: room air
- Vasoactive agents: none

Oximetry samples (rest)

<table>
<thead>
<tr>
<th>Sample Site</th>
<th>Hgb (g/dL)</th>
<th>O2 Sat (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FA</td>
<td>11.1</td>
<td>95.6</td>
</tr>
<tr>
<td>PA1</td>
<td>11.0</td>
<td>53.2</td>
</tr>
<tr>
<td>PA2</td>
<td>11.0</td>
<td>53.0</td>
</tr>
</tbody>
</table>

Assumed O2 consumption = 226.0 mL O2/min
- BMR = 0.5%
- A-V O2 Difference = 6.39 Vol %
- PBF (Qp) = 3.5 L/min
- PVR = 3.1 Wood units
- SBF (Qs) = 3.5 L/min
- SVR = 21.8 wood units
- Cardiac Index = 1.89 L/min/m²

Hemodynamic and Valve Data (resting state, in mmHg)
- RA: a=10, v=10, mean=8
- RV: 32/7, EDP 10
- PA: 32/17, mean=20
- PCW: a=8, v=12, mean=10
- Systemic BP: 120/78, mean 95

Coronary Angiography
Instruments: 6Fr JL4, 6Fr JL5, 6 Fr JR4, 6Fr dual lumen pigtail

Coronary anatomy
Dominance: right

<table>
<thead>
<tr>
<th>Segment</th>
<th>Stenosis</th>
<th>Lesion Type</th>
<th>TIMI Flow (abnormal)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prox RCA</td>
<td>30%</td>
<td>Discrete</td>
<td></td>
</tr>
<tr>
<td>Mid RCA</td>
<td>40%</td>
<td>Discrete</td>
<td></td>
</tr>
<tr>
<td>RPL1 (Small)</td>
<td>50%</td>
<td>Diffuse</td>
<td></td>
</tr>
<tr>
<td>RPL2 (Small)</td>
<td>50%</td>
<td>Diffuse</td>
<td></td>
</tr>
<tr>
<td>Mid LAD</td>
<td>20%</td>
<td>Discrete</td>
<td></td>
</tr>
<tr>
<td>*Mid LAD</td>
<td>70%</td>
<td>Discrete</td>
<td></td>
</tr>
<tr>
<td>Dist LAD</td>
<td>30%</td>
<td>Tubular</td>
<td></td>
</tr>
<tr>
<td>Left Main</td>
<td>normal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Left Circumflex</td>
<td>normal</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Denotes significant lesion

Notes: anterior takeoff of the RCA, unable to seat JR catheter
Left Ventriculography
Instruments: 6Fr dual lumen pigtail

Hemodynamics (mm Hg): 182/6, EDP 22
Ejection fraction: 55%
Wall motion: mild inferior hypokinesis, moderate apical hypokinesis
LV dilation: mild global dilation
Mean Ao-LV gradient: 45 mm Hg
Aortic valve area: 0.7 cm2

Interventions

Percutaneous Coronary Intervention
Lesion #1: OM2 90% TIMI 3 (pre) to normal TIMI 3 (post) (IRA)
  Guide catheters: Cordis 6Fr XB 3.0 Vista Britetip
  Guide wires: Guidant/ACS .014x300cm Whisper MS
  Devices:
    Abbott Mini Trek OTW 2.0x20mm (balloon)
    Medtronic Resolute Integrity 2.25x30mm (drug eluting stent) – max atm: 18
  Notes: Lesion did not open until 24 ATM applied with pre-dilation balloon

Lesion #2: L main body normal TIMI 3 (pre) to 50% TIMI 3 (interval) to normal TIMI 3 (post)
  Guide catheters: Cordis 6Fr XB 3.0 Vista Britetip
  Guide wires: Guidant/ACS .014x300cm Whisper MS, Abbott Balance Middleweight Universal
  Devices:
    Abbott Xience Rx Everolimus 4.0x12mm (drug eluting) stent
    Abbott NC Trek Rx 5.0x8mm (balloon)
  Notes: guide catheter trauma to left main; both LAD and LCX were wired

Right Ventricle Biopsy
Instruments: Bioptome Forcep MOB-1
Specimens removed: 4
Pathology slip: 44335544

Medication Totals

<table>
<thead>
<tr>
<th>Medication</th>
<th>Dose</th>
<th>Route</th>
<th>Time</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lidocaine</td>
<td>1%, 20 ml sq</td>
<td></td>
<td>14:10</td>
<td></td>
</tr>
<tr>
<td>Diphenhydramine</td>
<td>25 mg</td>
<td>iv</td>
<td>14:03</td>
<td></td>
</tr>
<tr>
<td>Hydromorphone</td>
<td>0.5 mg</td>
<td>iv</td>
<td>14:03</td>
<td></td>
</tr>
<tr>
<td>Midazolam</td>
<td>1.0 mg</td>
<td>iv</td>
<td>14:03</td>
<td></td>
</tr>
<tr>
<td>0.9% normal saline</td>
<td>50 ml</td>
<td>iv</td>
<td>14:03</td>
<td></td>
</tr>
<tr>
<td>Isovue</td>
<td>80 ml</td>
<td>iv</td>
<td></td>
<td>Lot number: 1F31882</td>
</tr>
</tbody>
</table>

Radiation
Fluoroscopy time: 4.5 minutes
Dose area product: 1.1 Gy-cm2
Cumulative air kerma: 1340 mGy
Estimated Blood Loss: 20 ml

Specimens Removed: RV biopsy x4

Final ICD Diagnoses
-  585.3 Chronic kidney disease, Stage 3 (moderate) - (GFR 59-30)
-  V42.1 Heart replaced by transplant
-  426.4 Right Bundle Branch Block (RBBB)
-  V58.65 Steroids, Long term (current) use of
-  401.1 Benign Essential Hypertension
-  V58.66 Aspirin, Long term (current use)

Procedure Notes
[This is for any additional text-based notes describing the specifics of the procedure]
Disclaimer

- The data displayed in the example cath report prototypes is derived from a series of patients and will be clinically inconsistent. The names are fictional. Any resemblance to actual patient data is purely coincidental. For the sake of clarity, many brand names of drugs and devices have not been changed. However, endorsement is not implied, suggested, or otherwise supported by the inclusion of brand name drugs and devices. (Some brand names have been changed or otherwise obfuscated.) What is important is the structure and formatting of the report – ignore the actual content and data presented in the report.

General

- A section (or item within a section) should only be displayed / printed if data is present. Items where there is no data should be suppressed, including the label associated with the data element. In general, items should not be listed with a value of “not applicable”, or have a computer-assigned value of “no” or “none” if the actual value is blank. Note: if negation of a data element is explicitly captured (e.g., history of PVD = no), then it should be displayed as such.
- Reduce superfluous clutter as much as possible. For a table of values, do not include units with each and every measurement, particularly if implicitly understood by convention (e.g., do not print “mm Hg” for each number of a hemodynamic measurement of a RHC such as systolic, diastolic and mean BP). Instead, place units in column headers or as a notation at the top of the table or at the end of a line.
- Represent findings in a noun: adjective (or label: value) motif, without verbs. For example: “EF: 61%”, not “The ejection fraction is 61%”.
- Every group of data (i.e., at the “paragraph” level) is to have a header, followed by indented text beginning 1 line down from section header. The paragraph header should be bold font, and can optionally be in color.
- In general, a group of concepts should be indented at 0.25” relative to the parent, with additional 0.25” indents as needed.
- Labels should be either left justified or right justified. In a 2 column table (label: value), if the values of a table are likely to be the same (e.g., “normal” for the segments of wall motion), then the corresponding labels should be right justified (so that the values all line up as left-justified). If there is a group of right-justified labels, the right justification setting should be at approximately 0.9” followed by data at a 1.0” tab. If the labels are too long to fit, use a right justification setting of approximately 1.4” followed by data at a 1.5” tab.
- The first word of a text string or phrase should be capitalized. All other letters of words should be in lower case. This includes trade and brand names of devices, even if the registered trademark is in all capitals.
- Minimum font size of text: 10. Preferred font size is 11 or 12 point.
- A blank line is to occur between each “paragraph”.

Sections of the Report

- The intent of the first “executive summary” page is to convey clinically relevant information ONLY and is purposefully NOT all-inclusive. The target length of this first section is 1 page or less of text. It should convey the key information that a physician and other members of a care team need to provide care: the procedures that were performed (including the vascular access route), the key diagnostic findings, intervention target and key intervention results, adverse events, and impressions and recommendations for care. It is intended to replace the handwritten procedure note authored immediately at the completion of a procedure.
- The second section includes graphics and images. Critical content is the graphical vascular tree diagram or other graphical depiction of the key findings, embracing the concept that a “picture is worth a thousand words”. The graphical diagram should be specific to the procedures performed;
certain procedure types (e.g., right heart catheterization, RV biopsy) may not have a diagram. A left heart catheterization with PCI should include a baseline coronary tree and a second page indicating the PCI location and results; similarly, a structural or peripheral vascular intervention should include pages that reflect both the baseline vascular anatomy and the intervention site with result. Similarly a structural intervention should display the intervention location with a notation about the results. Hemodynamic tracings relevant to the findings described in the report are to be included. Likewise, representative images captured (“cut and paste”) from the imaging systems (e.g., angiography, intravascular ultrasound, intracardiac echocardiography), including annotations embedded on those images are to be included in the second section.

- The third section includes all other non-image information needed in a complete report. While there is a substantial amount of content included in this section, this section should be considered more as a reference section. If the first section “executive summary” is done well, there should be little reason for clinicians to review the content in this section. The details are largely for regulatory compliance, administrative purposes, billing, and the assessment of appropriateness, quality, and process.

---

**Section 1 Content: The “Executive Summary”**

**Primary Indication:** Primary (single) indication for procedure, including ICD code and corresponding text phrase.

**History:** Analog text, in a paragraph format, with a suggested character limit of 500 characters (several sentences). This is a description of the patient’s presentation and context of the procedure, summarizing information available before the start of the procedure. This is not intended to include or convey data at the level of clinical data elements (e.g., a listing of CV risk factors) – rather, this is to reflect the thought process of the MD. A coded cardiac history (e.g., angina data and / or heart failure data) can be substituted.

**Procedures:** List of procedures, using common clinical phraseology (i.e., “MD-speak”, such as “left heart cath”, “percutaneous coronary intervention”) rolled up into a billable CPT code. Nomenclature is to be common (conventional clinical) terminology reflecting composite procedure concepts, not individually coded (CPT) procedure components – see the Cardiovascular Vocabulary for Electronic Health Records publication of the ACCF/AHA Task Force on Data Standards (Weintraub WS, Tcheng JE. et al, JACC 58:202-22, 2011) for a list of suggested procedure names. For interventions, list target(s) on the same line as procedure is listed if target cannot be determined by the name of procedure (e.g., the target would not need to be listed for a PFO closure or TAVR aortic valve implant, whereas a PCI procedure should state “percutaneous coronary intervention: proximal LAD, prox-mid LCX”). If more than 1 target, the list of targets is to be concatenated (i.e., do not create a separate line for each intervention).

**Vascular Access:** Include the brand name and size of sheaths used, and indicate if access was established by a cutdown / surgical access (but not if by standard percutaneous technique). Also note disposition of the sheath at the conclusion of the procedure. Include information about vascular closure if used.

**Catheters:** Concatenated, comma-separated list of the diagnostic and interventional catheters successfully used in the procedure, listing only the shorthand size (e.g., JL4) without manufacturer information or brand names of products. Do not list other devices (sheaths, guidewires, balloons, stents, etc.) in this section. Other than procedure findings and implanted device information, this is the most useful piece of information needed when a patient returns for a subsequent procedure.
**Diagnostic Findings:** Objective findings of the procedure. If there is sufficient room for 2 sets of columns, the preferred format is to have 2 separate 2 column lists of the key findings, keeping subsections (RHC, LV, coronaries, other findings) together. Headers are used for each subsection. Labels can be left justified at a +0.25” indent from the header, or right justified at approximately 0.9” for RHC and LV, with data values at 1.0”.

If a RHC is done, then the key RHC findings should be in the left hand column, and the left heart findings in a column on the right. If no RHC, then the coronary artery disease findings should be in a left column, and the LV findings should be in a column on the right.

**Interventions:** List of interventions, ideally presented as a single line per intervention. This should be a numbered list if more than 1 lesion. For stent PCI, list lesion(s) treated and stent parameters. List brand name of stent (but do not list manufacturer), stent length and diameter, and include in parentheses whether a bare metal or drug-eluting stent. For other PCI, list lesion treated and (in hierarchical order) list balloon if no stent and no other technology used, other technologies (e.g. rotational atherectomy, aspiration thrombectomy, covered stent) with stent (or final balloon if no stent) used. List in chronological order. List abnormal flow (TIMI 0, 1, or 2) or final % stenosis if not optimal (>30% if stent, >50% if balloon). For other interventions, anatomic structure treated and device parameters, along with abnormal result if not optimal.

**Adverse Events:** List of adverse events occurring during the procedure, with a single line per item. If no adverse events, state “None”.

**Medication Totals:** Summary tabulation of totals of medications administered during the procedure. Include listing of infusions running at the completion of the procedure. A two or three column format is preferable if possible.

**Contrast Total:** Summary total of the type of contrast used during the procedure and the total volume.

**Impressions:** An analog (text) box for description of summary findings and interpretations of the study. Suggested total character limit of 1000 characters. The intention is that this section should be short and succinct, perhaps a bulleted list. This section is not intended to include or convey information as clinical data elements.

**Recommendations:** An analog (text) box for recommendations arising from the cardiac catheterization. Suggested total character limit of 1000 characters. The intention is that this section should be short and succinct, perhaps a bulleted list. This section is not intended to include or convey information as clinical data elements.

**Operator:** identification of primary physician operator(s) and eSignature. An attestation can be included here if required.

---

**Section 3 Content: the Detailed Report**

**Patient**
Patient specific identifiers and other patient specific information

**Healthcare Facility**
Name, address, phone number and other information regarding the catheterization laboratory
Personnel
Operator, staff

Care Providers
Listing of all providers involved in the care of the patient, including a recapitulation of the information that accompanied the request for the cath procedure

Encounter Category: to include sufficient information for categorization of risk, per NCDR and other mortality risk models. This should also accommodate state registry (e.g., State of Massachusetts MASS-DAC) concepts of extremely high risk cases (i.e., salvage). Suggested categories:
- Elective diagnostic coronary cath
- Elective coronary cath, possible intervention
- Elective coronary intervention
- Elective [specify] diagnostic cath
- Elective [specify] intervention
- ACS/NSTEMI
- Acute STEMI
- Urgent non-coronary cath
- Emergency non-coronary cath
- Salvage / heroic / compassionate use

HISTORY and PHYSICAL

History: Analog text, in a paragraph format, replicated from the Summary page (optional).

Symptom Class: Structured data, reflecting the current angina class, heart failure class, etc.

Medical History: Structured data, identifying the presence of CV risk factors and other medical issues. If the absence of a CV risk factor is specifically captured, it should be displayed / printed on the report. If the absence of a CV risk factor is not captured, it should be suppressed.

Previous Procedures / Previous Events: Structured data, a listing of invasive and interventional procedures, along with pertinent clinical events (e.g., acute MI event and date). List date, with the date right justified, followed by the name of hospital (but not city / state), followed by shorthand notation regarding type of event and (if relevant) the key results.

Allergies and Sensitivities: Listing of allergen, reaction, and severity (c.f. HL7 standard for allergy reporting).

Physical Exam: Structured data, reflecting key cardiovascular physical exam findings relevant to cardiovascular catheterization

Laboratories: Structured data - suggested labs to include: hemoglobin, platelet count, potassium, BUN, and creatinine. Other labs can be reported if the patient is receiving antithrombotics (i.e., PT, INR, PTT). Optionally include reference ranges for the reported labs.

ICD Diagnoses: Complete list of indications for procedure and other conditions present relevant to the procedure, including ICD code and corresponding text phrase. This should represent a summary of the available information relevant to the cath procedure. Note that this is NOT the EHR problem list for the patient – only the diagnoses relevant to the procedure.
PROCEDURE

Note: Most of the data in this section is to be captured by the staff and documented in the hemodynamic (HD) monitoring system. This data should be transferred electronically from the HD monitoring system to the reporting system (and transformed by the reporting system to make it appropriate for the report) rather than being re-entered. These data should not be re-collected by the physician.

Procedures: This is a listing of the individual procedures that were performed, per CPT coding or other applicable current billing code system. The individual line items may be components that together comprise a CPT code. This is not intended to be a duplicate of the same section on the summary page, but instead a granular listing of each procedure and subcomponent procedure performed. This is primarily for administrative (billing) purposes.

Logistics: Inclusive of key time points (e.g., time patient entered the laboratory, time of departure).

Baseline Data: Inclusive of height, weight, calculation of BSA, starting HR and BP, and calculated eGFR.

Acute STEMI Logistics: List of key time points in the acute care of an emergency acute STEMI patient – target is for analysis of hospital and cath lab processes. Single line for each item. List times first, then event. Times should be colon (right) justified at 0.9”. List only the hh:mm time, not seconds, and not the date. Specific notes:

First medical contact, with selection in parentheses of EMS, OSH ED, or [my] Hospital ED – where EMS is Emergency Medical Services, outside hospital ED for patients transferred from another hospital, or [my] Hospital ED for patients who drive-in / walk-in
[my] Hospital arrival – if first medical contact is EMS or OSH ED. Suppress if first medical contact is [my] Hospital ED, as this would be redundant.
Cath lab arrival: include a notation about the pain grade on admission to the cath lab.
First device activation: include a notation about the type of the first device used (e.g., aspiration thrombectomy, balloon)
Final IRA angiogram: include a notation about the final percent stenosis, TIMI grade, and pain grade

Vascular Access: Include the manufacturer, brand, and size of sheaths used, and indicate whether access was percutaneous or via cutdown. Also note disposition of the sheath at the conclusion of the procedure. Include information about vascular closure if used.

Hemodynamic Support: Listing of hemodynamic support, including access route, time support initiated, and other pertinent notes. Listing of respiratory support, including time support initiated, anesthesiologist, ventilator parameters, and other pertinent notes.

RESULTS

Diagnostic Procedure: Listing of all of the catheters, wires, and devices used during the diagnostic cath portion of a procedure. This does not include sheaths (these should be listed in the vascular access section).
**Diagnostic Results**

**Right heart:** Labels for hemodynamic and oximetry measurements should be right aligned at 0.9”.

**Coronary anatomy:** Needs to anticipate diffuse disease that extends from one segment to another, as well as multiple focal stenoses within a given segment. Labels for vessel segments should be right justified at 0.9”. “Significant” disease is defined as >50% in a major epicardial vessel or a large branch, or left main >=50%. Lesion description is focal, tubular, or diffuse.

**Left heart:** Ventriculography should include a notation in parentheses regarding single vs biplane calculation. Labels for ventriculography should be right justified at 1.4”. Note the notations in parentheses in the prototype.

**Other procedures:** Follow the same general conventions as described above to organize and format the data for display / print.

**Intervention:** Listing of guide catheters, guidewires, and other equipment used to access the target lesions(s). This listing is organized by lesion, including identification and description of the target lesion(s) and the devices used to treat the lesion(s). Include manufacturer, brand, and size / parameters information with all devices. The size / parameters should be listed last in the text string. Anticipate use of the proposed FDA unique device identifier (UDI) standard. Of note, the results of an intervention are to be included in the same table.

**Medication Totals:** Summary tabulation of medication totals.

**Radiation:** Summary tabulation of radiation exposure parameters. Total fluoroscopy time should be reported as min:sec. Cumulative x-ray energy delivered to the interventional reference point (air kerma) should be reported as Gray (Gy). Dose burden (air kerma over the exposed x-ray field, or the kerma area product) should be reported as Gy*cm2.

**Estimated Blood Loss:** Estimate of blood loss, per Joint Commission requirements.

**Specimens Removed:** Source of specimens removed, or “none”.

**Final ICD Diagnoses:** List of all relevant ICD diagnoses based on all information accrued during the procedure.

**Procedure notes:** A text box for miscellaneous notes dictated or typed as analog text.
Table 1. Organization of the Structured Catheterization Procedure Report

Header (top of summary page, top of details section)
- Facility information: healthcare entity, catheterization laboratory location
- Patient identifiers: name, medical record number, date of birth, age
- Procedure date
- Physician operator
- Referring provider(s)

Section 1: Summary Page
1. Primary Indication
2. History
   a. 1-3 sentences of prose describing circumstances of the presentation
3. Procedures (list of procedures, grouping individual procedures together by composite CPT code)
4. Procedure details
   a. Vascular access site(s)
      i. Sheath size, sheath status at end of procedure, vascular closure method
   b. Catheters [diagnostic imaging / guide catheters]
      i. Diagnostic
      ii. Intervention
   c. Diagnostic findings [“Box 1” on sample report – see Table 2 for details]
      i. Findings, hemodynamics, calculations
   d. Interventions [“Box 2” on sample report – see Table 2 for details]
      i. Target lesions: devices implanted, results
5. Adverse Events
6. Medication and Contrast Totals
7. Impressions
   a. Prose listing of summary findings
8. Recommendations
   a. Prose listing of care recommendations

Section 2: Graphics and Images
1. Diagram (graphical tree representation) of vascular anatomy, annotated
   a. Diagnostic findings
   b. Intervention results
2. Image capture
   a. Hemodynamic tracings
   b. Images +/- annotations (embedded at a reduced resolution, with reference to DICOM image)

Section 3: Report Body
1. Administrative Information
   Patient
   - Patient full name, date of birth, age, gender
   - Race, ethnicity
   - Insurance
   - Medical record number
   - Case accession number (or other unique study ID)
   Healthcare Facility
• Complete facility information: name of healthcare entity, catheterization location (laboratory), address, FAX number, phone number, laboratory accreditation

Operator, Staff
• Referring Providers
• Primary care provider
• Cardiologist
• Reason for request (ideally, replica of information received via EHR)
• Procedure requested, date of request
• Requestor

Encounter Category
• Elective, urgent, emergency, salvage (and subcategories)

2. History and Physical
• Symptom class
• Medical history (risk factors - pertinent positives only, unless a negative finding is explicitly captured)
• Family history (pertinent positives only)
• Previous procedures and previous events, with pertinent results
• Allergies and sensitivities
• Physical examination (limited)
• Laboratory values (limited: BMP, WBC, Hgb, Hct, platelet, PT, INR, PTT)
• Procedure indications (ICD terminology)

3. Procedure
• Individual (component) procedures performed (as CPT codes, or using other standardized procedure terminology – these are not the aggregate procedures reported on the summary page)
• Logistics (time in, time out, consent / sedation consents, timeout performed, final patient condition and logistics)
• Starting vital signs: BP, pulse
• Access site (location(s), sheath(s) size and manufacturer, brand, other sheath information); sheath disposition at end of case, vascular hemostasis method
• Anesthesia support (if applicable)
• Surgical support (if applicable)
• Hemodynamic support (if applicable)
  o Type of support: when initiated (e.g., elective at the start of the case, planned for the case, urgent in response to a complication), and disposition at end of case

4. Diagnostic Findings

Diagnostic findings (organized by anatomic structure or physiologic function) [“Box 3” on sample procedure report – see Table 3 for details]
• Equipment
• Hemodynamic measurements, calculations (plus reference to DICOM Hemodynamics Report if applicable)
• Angiography findings, interpretations (plus reference to DICOM Quantitative Analysis Report if applicable)
5. Intervention (grouped by anatomic target, if multiple lesions treated) [“Box 4” on sample procedure report – see Table 3 for details]
   - Equipment
   - Baseline anatomy
   - Devices deployed, device deployment parameters
   - Intervention results

6. Summaries
   - Medications in-lab (time-stamped)
   - Drips running at completion of case (if applicable)
   - Contrast type and total
   - Radiation exposure (fluoroscopy time, dose area product, cumulative air kerma, reference to DICOM Dose Report)
   - Estimated blood loss
   - Specimens removed
   - Final ICD diagnoses
   - Final procedure notes
Table 2. Diagnostic Procedures Report Content. For each procedure, the content listed under the header “Summary Page” corresponds to content placed in Box 1 on the prototype report. Content listed under the header “Details Section” corresponds to content placed in Box 3 on the prototype report.

Diagnostic: Right / Left Heart Catheterization

Summary Page

Right heart cath
RA mean
RV systolic, diastolic, EDP
PA mean
PCW mean
AV 02 diff
Cardiac output, cardiac index
QpQs [only if not 1.0]
PVR, SVR

Details Section

Right heart | right / left heart catheterization
1. Assessment conditions: baseline / rest; [challenge with vasoactive agent]
   a. Patient height, weight, BSA
   b. Patient blood pressure, heart rate
   c. Inspired O2:
   d. Vasoactive agent [intravenous vasodilator, inhaled vasodilator, vasopressor, inotrope]:
2. Oxygen saturation (%)
   a. Innominate
   b. SVC
   c. IVC
   d. RA
   e. RV
   f. MPA
   g. LPA
   h. RPA
   i. LA
   j. Pulm vein
   k. LV
   l. Asc ao
   m. Desc ao
3. Pressures (mm Hg)
   a. Hepatic wedge: mean
   b. RA: a wave, v wave, mean
   c. RV: systolic / diastolic, end diastolic
   d. MPA: systolic / diastolic, mean
   e. RPA: systolic / diastolic, mean
   f. LPA: systolic / diastolic, mean
   g. RPCW: a wave, v wave, mean
h. LPCW: a wave, v wave, mean
i. LV: systolic / diastolic, end diastolic
j. Asc ao: systolic / diastolic, mean
k. Desc ao: systolic / diastolic, mean

4. Pressure gradients [specify mean / peak-peak / or both] (mm Hg)
   a. PCW-PA
   b. RPA-MPA
   c. LPA-MPA
   d. MPA-RV
   e. RV inflow-RV outflow
   f. RV-RA
   g. RA-hepatic wedge
   h. LA-LV diastolic
   i. LV inflow-LV outflow
   j. LV-Asc ao
   k. Asc ao-Desc ao

5. Calculations
   a. Hemoglobin: gm/dL
   b. O2 consumption: mL O2/min
   c. CO [method]: L/min
   d. CI: L/min/m2
   e. AVO2 diff: vol%
   f. Qp: L/min
   g. Qp index: L/min/m2
   h. Qs: L/min
   i. Qs index: L/min/m2
   j. Qp:Qs
   k. PVR: Wood units [or] dynes-sec/cm
   l. SVR: Wood units [or] dynes-sec/cm
   m. Valve area by [method]: cm²

Diagnostic: Congenital Disease Angiography

Summary Page

Angiography of [structure]: summary findings

Details Section (table)

<table>
<thead>
<tr>
<th>Structure</th>
<th>Catheter</th>
<th>Angles</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>RA angiogram</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Right ventriculogram</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MPA angiogram</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RPA angiogram</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LPA angiogram</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RPAW angiogram</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LPAW angiogram</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RUPV angiogram</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Left ventriculogram</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ascending aortogram</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Descending aortogram</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Other angiogram [specify location, e.g., MAPCA, decompressing vein, collaterals]

**Diagnostic: Left Heart Cath / Left Ventriculography / Aortography**

**Summary Page**

- **Pressures:**
  - Aorta: systolic / diastolic, mean
  - Left ventricle: systolic / diastolic, LVEDP

- **Left ventriculogram**
  - Ejection fraction
  - LV segmental wall motion: [abnormal only; if none, then “normal”]
  - Mitral regurgitation: [grade]
  - Other findings: [describe]

**Details Section**

- **Pressures:**
  - Aorta: systolic / diastolic, mean
  - Left ventricle: systolic / diastolic, LVEDP

- **Left ventriculogram**
  - Ejection fraction
  - LV segmental wall motion: [table of all segments per the 5 segment model: RAO includes anterior, apical, inferior; LAO includes septal, posterolateral segments]
  - Mitral regurgitation: [grade]
  - Other findings: [describe]

- **Aortogram**
  - Findings: [describe]

**Diagnostic: Coronary Arteriography**

**Summary Page**

- **Pressures:**
  - Aorta: systolic / diastolic, mean

- **Coronary angiography (summary findings)**
  - Dominance: [if not right dominant]
  - Left main: [normal, insignificant, or list of significant lesions]
  - Left anterior descending: [normal, insignificant, or list of significant lesions]
  - Left circumflex: [normal, insignificant, or list of significant lesions]
  - Right coronary: [normal, insignificant, or list of significant lesions]
  - Number of diseased vessels: [0, 1, 2, 3]

- **Graft angiography**
  - Number of grafts (origins)
  - Number of distal anastomoses placed
  - Number of distal anastomoses patent
  - Significant graft lesions
Details Section

Coronary angiography (table)
   Dominance
   Artery-segment (size) % Stenosis Descriptors TIMI flow

Graft angiography (table)
   Graft type-anastomosis Segment % Stenosis Descriptors TIMI flow

Adjunctive diagnostic assessment (table)
   Modality Segment Findings
   [FFR]          [IVUS]
   [OCT]

Diagnostic: Peripheral Arteriography

Summary Page

Peripheral vascular angiography (summary findings)
   [Vessel / segment]: [normal, insignificant, or list of significant lesions]
   Graft angiography: [normal, insignificant, or list of significant lesions]
   Number of diseased leg vessel segments: [based on aorto-iliac, femoro-
                                           popliteal, and tibial-crural segmentation schema]

Details Section

   Number of diseased leg vessel segments: [based on aorto-iliac, femoro-
                                           popliteal, and tibial-crural segmentation schema]

Peripheral vascular angiography (table)
   Artery-segment Stenosis Lesion type

Graft angiography (table)
   Graft type-anastomosis Segment Stenosis Lesion type

Adjunctive imaging (table)
   Modality Segment Findings

Diagnostic: Cerebrovascular Arteriography

Summary Page

Aortic arch type
Cerebrovascular angiography (summary of lesions in injected arteries): [normal, 
   insignificant, or list of significant lesions]

Details Section

   Aortic arch type (i.e. Types 1-3, bovine)
   Hemispheric cross-filling
   Cerebrovascular angiography (table)
      Artery-segment Stenosis Lesion type
### Table 3. Intervention: Coronary Artery Disease

#### Summary Page

PCI of [coronary segment]

Devices: [type(s) of interventions – e.g. balloon angioplasty, atherectomy, stent implantation, aspiration thrombectomy, etc.]; stent - brand name, diameter x length, bare metal or drug-eluting, UDI; final balloon if no stent

Results: pre % stenosis to post % stenosis [pre TIMI flow to post TIMI flow, if either abnormal (i.e., not TIMI 3); no reflow]

#### Details Section

PCI of [coronary segment]

Intervention:

- Guide catheters: manufacturer, Fr size, model
- Guide wires: manufacturer, diameter, model
- Devices: balloons – timing (pre versus post stent implantation), diameter x length, max pressure x duration; other devices – with parameters; stent – manufacturer, brand name, diameter x length, max pressure x duration, bare metal or drug-eluting, UDI

Results: pre % stenosis to post % stenosis [pre TIMI flow to post TIMI flow, if either abnormal (i.e., not TIMI 3); no reflow]

Technical notes (analog text)

### Intervention: Peripheral Artery Disease

#### Summary Page

PVI of [peripheral artery segment]

Devices: [type(s) of interventions – e.g. balloon angioplasty, atherectomy, stent implantation, etc.]; stent - brand name, diameter x length, bare metal or drug-eluting, UDI; final balloon if no stent

Results: pre % stenosis to post % stenosis [pre TIMI flow to post TIMI flow, if either abnormal (i.e., not TIMI 3)]

#### Details Section

PVI of [peripheral artery segment]

Intervention:

- Guide catheters: manufacturer, Fr size, model
- Guide wires: manufacturer, diameter, model
- Devices: balloons – timing (pre versus post stent implantation), diameter x length, max pressure x duration; other devices – with parameters; stent – manufacturer, brand name, diameter x length, max pressure x duration, bare metal or drug-eluting, UDI

Results: pre % stenosis to post % stenosis [pre TIMI flow to post TIMI flow, if either abnormal (i.e., not TIMI 3)]

Technical notes (analog text)

### Intervention: Cerebrovascular Disease
Summary Page

PTA of [cerebrovascular artery segment]
Devices: [type(s) of interventions – e.g. balloon angioplasty, atherectomy, stent implantation]; embolism protection; stent - brand name, diameter x length, bare metal or drug-eluting, UDI
Results: pre % stenosis to post % stenosis

Details Section

PTA of [cerebrovascular artery segment]
Intervention:
Guide catheters: manufacturer, Fr size, model
Guide wires: manufacturer, diameter, model
Devices: balloons – timing (pre versus post stent implantation), diameter x length, max pressure x duration; embolism protection – manufacturer, brand name, timing; other devices – with parameters; stent – manufacturer, brand name, diameter x length, max pressure x duration, bare metal or drug-eluting, UDI
Results: pre % stenosis to post % stenosis
Technical notes (analog text)

Intervention: Transcatheter Aortic Valve Replacement (TAVR)

Summary Page

Intervention: valve – manufacturer, brand name, size; de novo or valve in valve
Results: mean gradient pre to mean gradient post; regurgitation post – grade and location (paravalvular, central)

Details Section

Angiography
a. Femoral artery angiogram: RFA / LFA, findings
b. Ascending aorta angiogram: findings
Aortic valve - baseline
a. Previous aortic valve bioprosthesis (make and size)
b. Dimensions by [CT / MR / echo]
   Annulus (mm):
   STJ (mm):
   Sinus segment (mm):
c. Hemodynamic assessment
   LV pressure
   Asc aorta pressure
   Peak-peak gradient, mean gradient
   Valve area by [method]:
   Measurement condition: resting / inotrope and dose
Intervention
a. RV pacing
   Rate:
   Timing: (when pacing used during procedure)
b. Balloon aortic valvuloplasty:
   
   Guide wire: manufacturer, diameter, model
   Balloon – manufacturer, brand name, diameter x length
   Inflation duration (sec):
   Inflation pressure (atm):

c. Transcatheter aortic valve replacement
   
   Valve system – manufacturer, brand name, size
   De novo or valve in valve

d. Maldeployment – present or absent; if present:
   
   Valve embolization: LV or aortic
   Management: open conversion, deployment in desc thoracic ao

Results:

a. Hemodynamic assessment
   
   LV pressure
   Asc aorta pressure
   Peak-peak gradient, mean gradient
   Valve area by [method]:
   Measurement condition: resting / inotrope and dose

b. Ascending aorta angiogram:
   
   Paravalvular regurgitation: [none, 1+, 2+, 3+, 4+]

c. Iliac / femoral artery angiogram: findings

d. Transesophageal echocardiogram
   
   Paravalvular regurgitation: [none, 1+, 2+, 3+, 4+]
   Central regurgitation: [none, 1+, 2+, 3+, 4+]

Access Site Closure

a. Closure method: open surgical, closure device – manufacturer, brand name

b. Angiogram: findings

c. Crossover technique
   
   Sheath used – manufacturer, brand, size; balloon used –
   manufacturer, brand, size

### Intervention: Congenital Stenosis

Summary Page

Target: RPA, LPA, Coarctation, other stenosis [specify lesion]
Devices: [type(s) of interventions – e.g. balloon angioplasty, stent implantation]; stent - brand name, diameter x length, bare metal or covered, UDI
Results: gradient pre to gradient post; MLD pre to MLD post

Details Section

Target: RPA, LPA, Coarctation, other stenosis [specify lesion]

Intervention:
   
   Guide catheters: manufacturer, Fr size, model
   Guide wires: manufacturer, diameter, model
   Devices: balloons – timing (pre versus post stent implantation), diameter x length, max pressure x duration; other devices – with parameters; stent – manufacturer, brand name, diameter x length, max pressure x duration, bare metal or covered, UDI
Results: gradient pre to gradient post; MLD pre to MLD post; nominal (adjacent) diameter (PA stenosis); isthmus and descending ao @ diaphragm diameter (coarct)

Technical notes (analog text)

**Intervention: Valvuloplasty**

**Summary Page**
- Target: aortic valve, mitral valve, pulmonic valve, tricuspid valve
- Devices: final balloon – diameter x length
- Results: gradient pre to gradient post; MLD pre to MLD post

**Details Section**
- Target: aortic valve, mitral valve, pulmonic valve, tricuspid valve; annulus diameter
- Intervention:
  - Guide wires: manufacturer, diameter, model
  - Devices: balloons – diameter x length, max pressure x duration
- Results: peak-peak gradient pre to post; mean gradient pre to post, valve area by [method] pre to post
  - Measurement condition, pre: resting / inotrope and dose
  - Measurement condition, post: resting / inotrope and dose
- Technical notes (analog text)

**Intervention: Defect Closure**

**Summary Page**
- Target: ASD, PFO, PDA, VSD, fistula, other defect [specify defect]
- Devices: closure device - brand name, size, UDI
- Result: successful closure, unsuccessful closure

**Details Section**
- Target: ASD, PDA, VSD, other defect [specify defect]
  - ASD characteristics:
    - ASD type:
    - Size by echo (mm):
    - Size by balloon (mm):
    - Anterior rim, posterior rim, inferior rim, superior rim
  - PFO characteristics:
    - Size by echo (mm):
    - Size by balloon (mm):
  - PDA characteristics:
    - Size at pulmonic end (mm):
    - Length (mm):
  - VSD characteristics:
    - VSD location:
    - VSD size (mm):
  - Aortopulmonary collateral:
APC location:
Coronary fistula
Fistula location
Other abnormal conduit:
Conduit location / description:

Intervention:
Guide catheters: manufacturer, Fr size, model
Guide wires: manufacturer, diameter, model
Devices: balloons – manufacturer, brand name, diameter x length; closure
device – manufacturer, brand name, size, UDI

Results: successful closure, unsuccessful closure

**Intervention: Cardiac Biopsy**

Summary Page

Biopsy: [location] x [# specimens]

Details Section

Biopsy: right ventricle [or other location]
Guide catheter: manufacturer, Fr size, model
Bioptome: manufacturer, model
Number of specimens removed:
Pathology requisition number:
Abbreviations in this table:

Ao: aorta
APC: aortopulmonary collateral
Asc: ascending
ASD: atrial septal defect
Atm: atmospheres
Desc: descending
Fr: French
LFA: left femoral artery
LPA: left pulmonary artery
LV: left ventricle
MLD: minimum luminal diameter
PA: pulmonary artery
PCI: percutaneous coronary intervention
PDA: patent ductus arteriosus
PFO: patent foramen ovale
PTA: percutaneous transluminal angioplasty
PVI: peripheral vascular intervention
RFA: right femoral artery
RPA: right pulmonary artery
RV: right ventricle
Sec: seconds
STJ: sinotubular junction
TIMI: Thrombolysis in Myocardial Infarction
UDI: unique device identifier
VSD: ventricular septal defect
### Appendix 1. AUTHOR RELATIONSHIPS WITH INDUSTRY AND OTHERS ENTITIES (COMPREHENSIVE) - ACC/AHA/SCAI 2014 Health Policy

Statement on Structured Reporting for the Cardiac Catheterization Laboratory

<table>
<thead>
<tr>
<th>Committee Member</th>
<th>Employment</th>
<th>Consultant</th>
<th>Speaker’s Bureau</th>
<th>Ownership/Partnership/Principal</th>
<th>Personal Research</th>
<th>Institutional, Organizational, or Other Financial Benefit</th>
<th>Expert Witness</th>
</tr>
</thead>
<tbody>
<tr>
<td>Timothy Sanborn (Chair)</td>
<td>NorthShore University HealthSystem—Head, Division of Cardiology</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>James Tcheng (Vice Chair)</td>
<td>Duke University Medical Center—Professor of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>NIH* FDA*</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>H. Vernon Anderson</td>
<td>University of Texas Cardiology Division—Professor of Medicine</td>
<td>• Symbios</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Charlie Chambers</td>
<td>Penn State Milton S. Hershey Medical Center—Professor of Medicine and Radiology</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Sharon L. Cheatham</td>
<td>Nationwide Children's Hospital—PhD, Interventional Cardiology Nurse Practitioner</td>
<td>• Medtronic*</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• NuMED*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• St Jude Medical*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Toshiba Medical*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Matthew V. DeCaro</td>
<td>Jefferson University Hospitals—Director, Coronary Care Unit; Assistant Professor</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Jeremy Durack</td>
<td>Memorial Sloan-Kettering Cancer Center—Interventional</td>
<td>• Becton Dickinson</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Carestream Health*</td>
<td>None</td>
</tr>
<tr>
<td>Committee Member</td>
<td>Employment</td>
<td>Consultant</td>
<td>Speaker’s Bureau</td>
<td>Ownership/Partnership/Principal</td>
<td>Personal Research</td>
<td>Institutional, Organizational, or Other Financial Benefit</td>
<td>Expert Witness</td>
</tr>
<tr>
<td>---------------------------------------</td>
<td>------------------------------------------------------</td>
<td>------------</td>
<td>------------------</td>
<td>-------------------------------</td>
<td>------------------</td>
<td>----------------------------------------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Allen Everett</td>
<td>Johns Hopkins Hospital—Associate Professor Pediatric Cardiology</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Radiology† • Society of Interventional Radiology Foundation*</td>
<td>None</td>
</tr>
<tr>
<td>John Gordon</td>
<td>San Diego Cardiac Center Medical Corporation—Cardiologist</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>William Hammond</td>
<td>Duke Center for Health Informatics—Director</td>
<td>• Duke University Medical Center—Professor of Community and Family Medicine</td>
<td>None</td>
<td>None</td>
<td>NIH†</td>
<td>NIH • HL7 Standards</td>
<td>None</td>
</tr>
<tr>
<td>Ziyad Hijazi</td>
<td>James A. Hunter, MD, University, Rush Center for Congenital &amp; Structural Heart Disease—Chair Professor of Pediatrics &amp; Internal Medicine Director</td>
<td>• Edwards Lifesciences* • NuMED* • Occlutech*</td>
<td>None</td>
<td>• Colibri Heart Valve†</td>
<td>None</td>
<td>• PICS Foundation†</td>
<td>None</td>
</tr>
<tr>
<td>Vikram S. Kashyap</td>
<td>Case Western Reserve University, Harrington Heart &amp; Vascular Institute, University Hospitals Case Medical Center—Professor of</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Medtronic† • NIH*</td>
<td>None</td>
</tr>
<tr>
<td>Committee Member</td>
<td>Employment</td>
<td>Consultant</td>
<td>Speaker’s Bureau</td>
<td>Ownership/Partnership/Principal</td>
<td>Personal Research</td>
<td>Institutional, Organizational, or Other Financial Benefit</td>
<td>Expert Witness</td>
</tr>
<tr>
<td>------------------</td>
<td>-------------</td>
<td>------------</td>
<td>------------------</td>
<td>--------------------------------</td>
<td>------------------</td>
<td>--------------------------------------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Merrill Knudtson</td>
<td>University of Calgary—Professor of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>• Intellectual Property Agreement with U of C – Coronary anatomy reporting software</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Michael Landzberg</td>
<td>Boston Adult Congenital Heart (BACH) and Pulmonary Hypertension Group, Director</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>• Actelion • Gilead • NMT Medical</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Marco A. Martinez-Rios</td>
<td>Instituto Nacional de Cardiologia de Mexico</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Lisa Riggs</td>
<td>St. Luke’s Hospital—Director of Quality</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>• 2012, Defendant, Post Procedural Bleeding</td>
</tr>
<tr>
<td>Kui Hian Sim</td>
<td>Sarawak General Hospital, Heart Centre, Malaysia—Visiting Senior Consultant Cardiologist</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>• Advisory Board for pharmaceutical company in Malaysia • Principle Investigators, Malaysia govt research grant</td>
<td>• AstraZeneca • Abbott • Bayer • Boston Scientific • Eli Lily • MSD • National Heart Association of Malaysia†</td>
<td>None</td>
</tr>
<tr>
<td>Committee Member</td>
<td>Employment</td>
<td>Consultant</td>
<td>Speaker’s Bureau</td>
<td>Ownership/Partnership/Principal</td>
<td>Personal Research</td>
<td>Institutional, Organizational, or Other Financial Benefit</td>
<td>Expert Witness</td>
</tr>
<tr>
<td>------------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>------------</td>
<td>-----------------</td>
<td>---------------------------------</td>
<td>-------------------</td>
<td>-----------------------------------------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>David Slotwiner</td>
<td>Long Island Jewish Medical Center—Associate Director, Electrophysiology Laboratory</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>• Boston Scientific†</td>
<td>None</td>
</tr>
<tr>
<td>Harry Solomon</td>
<td>GE Healthcare—Interoperability Architect</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>• GE Healthcare*</td>
<td>None</td>
</tr>
<tr>
<td>Wilson Y. Szeto</td>
<td>University of Pennsylvania Medical Center, Division of Cardiovascular Surgery – Associate Professor of Surgery</td>
<td>• Microinterventional Device</td>
<td>None</td>
<td>None</td>
<td>• Edwards Lifesciences • Medtronic</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Bonnie Weiner</td>
<td>St. Vincent Hospital Worcester Medical Center—Training Director</td>
<td>• Atheromed • Atricure • Cersys/Surpass</td>
<td>None</td>
<td>• Imaging Core Lab Services†</td>
<td>• Accreditation for Cardiovascular Excellence* • SCAI, Past President</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>William Weintraub</td>
<td>Christiana Care Health System—Section Chief, Cardiology</td>
<td>• Amarin • Bristol Myers Squibb • Eli Lilly • Pfizer</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>• 2012, Defendant, Celebrex Litigation • 2011, Defendant, Oral Contraceptive Litigation</td>
<td>None</td>
</tr>
<tr>
<td>John Windle</td>
<td>University of Nebraska Medical Center Cardiology Section—Professor and Chief, Internal Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>• AHA* • NIH* • WebMD*</td>
<td>None</td>
</tr>
</tbody>
</table>
This table represents all healthcare relationships of committee members with industry and other entities by authors, including those not deemed to be relevant, at the time this document was under development. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$10,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to http://www.cardiosource.org/Science-And-Quality/Practice-Guidelines-and-Quality-Standards/Relationships-With-Industry-Policy.aspx for definitions of disclosure categories or additional information about the ACCF Disclosure Policy for Writing Committees.

*Significant relationship.
†No financial benefit.